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AUC Area under the curve; usually this applies to the receiver operating characteristic curve.
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S2k S-Class of a Guideline. According to the AWMF, S-Classes categorise the scientific methodology
of guidelines.
ScvO2 Central venous oxygen saturation
SPV Systolic pressure variation
SV Stroke volume
SVV Stroke volume variation
TEE Transoesophageal Echocardiography
TTE Transthoracic Echocardiography
VO2 (I) Oxygen consumption (index)
Rationale and goals
A1: Introduction
Medical guidelines present a systematically developed
body of information and advice to assist diagnosis and
treatment of specific health problems.1 They define
standard practice for tackling a key health issue, and
offer guidance to medical personnel and patients alike.2
Guidelines make an important contribution to rational
and transparent decision making in healthcare provision,
and their dissemination is intended to improve the qual-
ity of this provision.
The process used to develop guidelines must be sys-
tematic, independent and transparent.3 As defined by the
Arbeitsgemeinschaft der Wissenschaftlichen Medizi-
nischen Fachgesellschaften (AWMF; Association of
the Scientific Medical Societies in Germany), three
‘S-Classes’ are recognised within this process (Table 1).
The S-Class of the present Guideline is S-Class 3.
A2: Initial situation
Intravascular volume and fluid therapy is fundamental to
the management of adult inpatients. The concept applies
to all contexts and situations in which oral or enteral
delivery of fluids is unable to meet fluid intake needs.
The quantitative significance of intravascular volume
therapy is justified merely by the fact that the vast
majority of the 20 million patients approximately, treated
in German hospitals every year (https://www.destatis.de/
DE/ZahlenFakten/GesellschaftStaat/Gesundheit/Kran
kenhaeuser/Krankenhaeuser.html) require intravascular
volume therapy at least on a temporary basis. This mayight © European Society of Anaesthesiology. Un
Table 1 Guideline development S-Classes as defined by the Arbeitsg
Fachgesellschaften
S-Class 1: Expert group An expert group formed of representa
recommendation that is adopted by
S-Class 2: Formal evidence-based
research or formal consensus
building
Guideline development is based on the
consultation and adoption is based
group process, Delphi technique or
S-Class 3: Guideline with all elements
of systematic development
Guideline development comprises syst
recommendations according to the
Source: http://www.awmf.org/leitlinien/awmf-regelwerk/ll-register.html
Eur J Anaesthesiol 2016; 33:488–521be provided as a perioperative or peri-interventional
measurewhenever fasting is indicated formedical reasons,
when the enteral fluid resorption rate falls below the
necessary substitution rate (e.g. because of shock), in
the event of high-fluid turnover rates duringmajor surgery,
or in cases of reduced enteral resorption because of sus-
tained vomiting or severe diarrhoea.
Some recent multicentre studies have also triggered
debate about the benefits and risks of previous therapeutic
models basedonpathophysiological findings.One result of
this discussion has been the initiation of pharmacovigi-
lance proceedings concerning the use of Hydroxyethyl
starch (HES) by the European Medicines Agency (EMA)
inNovember 2012, during the development of the present
Guideline. The Pharmacovigilance Risk Assessment
Committee advises against its use in patients suffering
from sepsis and burns. (http://www.ema.europa.eu/ema/
index.jsp?curl=pages/medicines/human/referrals/Hydrox
yethyl_starch-contain ing_solutions/human_referral_prac_
000012.jsp&mid=WC0b01ac05805c516f)The recommen-
dations of the presentAWMFS3Guideline are based on an
analysis of the evidence and are to be viewed separately
from the EMA recommendations.
Spurred on by the general importance of the subject
and the uncertainties prevailing among its member
physicians, the German Society of Anaesthesiology and
Intensive Care Medicine has decided to initiate and
coordinate the development of a Guideline to be issued
by theAWMFas a contribution to evidence-based volume
therapy.authorized reproduction of this article is prohibited.
emeinschaft der Wissenschaftlichen Medizinischen
tive members of the specialist association(s) works in loose consensus on a
the Board(s) of the specialist association(s)
formal assessment of statements from the research literature (S2e) or guideline
on one of the following proven methods of achieving formal consensus: nominal
consensus conference
ematic literature research and assessment, the classification of case studies and
criteria of evidence-based medicine, and formal consensus building
Cop
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The Guideline must meet the following requirements: Byrased on current findings from research as well as
established practice, it provides support for decision
making in specific situations. It facilitates sound intravascular volume therapy for the
vast majority of adult inpatients. It is routinely assessed and updated to reflect current
knowledge on a regular basis. Through regular discussion with all stakeholders
(physicians, nursing staff, patients and relatives) it
achieves transparency for intravascular volume therapy
goals and procedures. It acknowledges that in light of the many situations in
which intravascular volume therapy is required, a
single treatment concept that meets all needs is
impossible to achieve.
A4: Guideline objectives
Overall, the Guideline aims to improve the quality of
volume therapy in peri-interventional or critically ill adult
inpatients. The best volume therapy should include a
correct indication (diagnosis of volume depletion), cor-
rect dosage (volume therapy management) and the selec-
tion of the infusion solution best suited to the patient.
There are competing concepts for each of these three
areas. By promoting effective, correctly dosed, efficient
and evidence-based volume therapy with the best benefit
to risk balance, the Guideline aims to secure the best
treatment of volume depletion in adult patients treated in
medical units throughout all levels of the healthcare
system.
The Guideline’s recommendations are intended to
further improve the quality of hospitals’ structures and
procedures, and help improve the quality of results. For
this reason, the Guideline can and should be used in
acute treatment situations, and in discussions about local
protocols, in quality assurance and any other appropriate
forum.
Since the Guideline authors wish to stimulate discussion
about volume therapy, criticism and proposals for
improvement are expressly requested. Ideally, recom-
mended amendments should be concisely summarised,
substantiated with references, and forwarded to the pub-
lisher.
The Guideline does not concern itself with the topic of
infusion therapy for patients without volume depletion
(as part of parenteral feeding and the correction of
electrolyte or acid-base imbalances, or infusions used
as carrier solutions for drug delivery). Nor does it
concern itself with blood product therapy; here, the
Guideline Group refers the reader to the appropriate
cross-sectional Guideline from the German Medical
Association.ight © European Society of Anaesthesiology. UA5: Target user group
The Guideline is addressed primarily to healthcare pro-
fessionals who are familiar with one or more aspects of
intravascular volume therapy for inpatients (diagnostics,
choice of solution and therapy management). Such pro-
fessionals will generally be physicians and nursing staff.
TheGuideline also addresses individuals wishing to learn
about evidence-based intravascular volume therapy for
adult inpatients. This group includes members of other
medical professions as well as patients and their families.
B: Methodology
The Guideline project was registered at the homepage of
the AWMF (Association of the Scientific Medical
Societies in Germany) on 7 October 2011 (http://www.
awmf.org).
B1: Literature search and selection of evidence
Use of existing guidelines
At the start of the project, a systematic guideline search
was conducted in guideline databases (National Guide-
line Clearinghouse, USA; Association of the Scientific
Medical Societies, Germany; Guideline International
Network, Scotland) and assessed for the potential reuse
of material. As this process failed to identify any guide-
lines that satisfied the inclusion criteria in full, a decision
was made to proceed with development of the Guideline
de novo.
Systematic literature search
Taking the key issues as its starting-point, the Methods
team from the Institut fu¨r Forschung in der Operativen
Medizin (Institute for Research in Operative Medicine)
worked closely with clinical experts to develop the strat-
egies for a systematic literature search for the diagnosis
and treatment of volume deficiency. Consensus was
achieved for these strategies by the Guideline Group
at the consensus conference of 17 April 2012, and they
were used on 21 May 2012 (follow-up search: 14 June
2013) for a literature search in Medline (via PubMed),
Embase and Cochrane Central Register of Controlled
Trials (CENTRAL) databases. Alongside medical key-
words (medical subject headings, MeSH) enhanced by a
free-text search, study filters were applied to identify
relevant systematic reviews and meta-analyses, (non)
randomised controlled trials, prospective cohort studies
and diagnostic studies (including cross-sectional studies).
Publication languages were restricted to German and
English, and within a publication time frame ranging
from 1995 to the date of the literature search. A flowchart
showing the numbers of retrieved, excluded, and
included publications can be seen in Fig. 1.
In addition, www.clinicaltrials.gov was searched on 14
June 2013 for completed but not yet published clinical
trials.nauthorized reproduction of this article is prohibited.
Eur J Anaesthesiol 2016; 33:488–521
Copyr
492 Marx et al.
Fig. 1
Primary search
(21.05.2012)
n = 19.892
Follow up search
(14.06.2013)
n = 2.061
Duplicate copies
n = 4.055
Excluded abstracts
n = 17.138
Full text papers to be
screened
n = 762  
Included full text
papers:
n = 248 
Full texts papers
identified by experts
n = 2
Excluded full text 
papers 
(violated inclusion criteria are
itemised): 
I1: n = 51
I2: n = 134
I3: n= 237
I4: n = 2
I5: n = 0 
I6 n = 6
I7: n = 3
I8: n = 29
I9: n = 15
I10: n = 36
I11: n = 1
Total: n = 514  
Abstracts to be
screened
n = 17.898 
Flowchart of included references and abstracts and the screening process. Indicators of violated inclusion criteria (I1 to I11) are explained in Table 2.
For each reference, only the first criterion violated was registered.Apart from this systematic search, each member of the
Guideline Group could recommend further publications
for inclusion in the evidence base. All publications,
whether retrieved by systematic database research or
by personal recommendation, passed through the screen-
ing, extraction and appraisal process described below.
Selection of literature identified
Two independent experts (one a methodologist, one a
clinician) screened every retrieved publication for the
prospectively defined inclusion criteria.2 The violation ofight © European Society of Anaesthesiology. Un
Eur J Anaesthesiol 2016; 33:488–521any inclusion criterion resulted in the exclusion of the
publication. Screening was performed at the level of the
title and abstract for all of the publications identified by
the search, and at the full-text level for studies still
included after the title/abstract screening.
When both experts agreed in their judgement on a study,
it was then included or excluded; where opinions dif-
fered, consensus was achieved by discussion between the
experts. Where consensus was not achieved, the Coordi-
nation Group decided on inclusion/exclusion. The study
selection flowchart is presented in Fig. 1.authorized reproduction of this article is prohibited.
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Table 2 Inclusion criteria for the retrieved references
Indicator Description
I1 80% of included patients were adults with intravascular (hypovolaemia) or interstitial (dehydration) fluid deficit in the context of any operative or
interventional procedure or an intensive care treatment. They did not have chronic renal failure requiring dialysis.
I2 Therapeutic intervention: intravascular fluid therapy with colloids (no dextrans) or crystalloids compared against each other or against placebo with
regard to elimination or course of the fluid deficit and to patient-relevant endpoints1) or diagnostic intervention: diagnoses of hypovolaemia or
dehydration by the use of specified criteria or diagnostic procedures1)
1)Mortality/survival: ICU, hospital, specified period and risk adjusted. Morbidity: hypervolemia, organ failure, acid base disturbance, allergic reactions,
coagulopathy, abdominal compartment, sepsis, pruritus and impaired wound healing. Quality of life. Surrogates: fluid balance; ventilator or
vasopressor-free days; vasopressor dosage; volume, pressure, or flow-based variables; dynamic methods (SVV, passive leg raising, etc.); clinical
signs of hypoperfusion; metabolic variables (ScvO2, lactate, etc.); microcirculatory parameters
I3 Article describes a randomized controlled trial, a quasi-randomised controlled trial, a clinical controlled trial, a prospective cohort study, a cross-
sectional study or a systematic review/meta-analysis including the study types mentioned
I4 Sample size: n20 (n<20 possible for clinical studies focussing on adverse events)
I5 The reference was published between 1995 and the day of the literature search
I6 The article is written in English or German
I7 The reference is not an additional publication without additional infomation
I8 The full-text study can be acquired
I9 The infusion used is approved for use in Germany (including off label use)
I10 The article was not retracted and the verisimilitude is not doubted. In systematic reviews, retracted or dubious studies can be separated
I11 The article allows comparison of the study with others with regard to methodology, reporting, and internal validity
A reference that violated a single criterion was excluded. ScvO2, central venous oxygen saturation; SVV, stroke volume variation.B2: Appraisal and extraction of evidence
Each study included following the full-text screening was
assigned to one or more key issues by the clinical expert.
The methodological appraisal was conducted in accord-
ance with the National Institute for Health and Care
Excellence (UK) Methodology Checklist (http://publica
tions.nice.org.uk/the-guidelines-manual-appendices-bi-
pmg6b#close). The checklists can be requested from the
corresponding author.
Methodological weaknesses were listed in the evidence
tables. The checklists were also applied to determine the
level of evidence (LoE) in accordance with the classifi-
cation supplied by the Oxford Centre for Evidence-
Based Medicine (version 2009). (http://www.cebm.net/
oxford-centre-evidence-based-medicine-levels-evidence-
march-2009/) To simplify future updates and to improve
comparability, the grading in accordancewith version 2011
(http://www.cebm.net/index.aspx?o=5653) was used in
parallel.
As a final step, evidence tables were created in extraction
templates with a priori consensus: these contained all of
the data from the respective publication relevant for
the infusion therapy and study methodology, plus the
authors’ conclusions and personal conclusions of the
Methods team. These evidence tables, written in Ger-
man, can be downloaded at http://www.awmf.org/leitli
nien/detail/ll/001-020.html. The data extraction, the
appraisal of the study methodology and the quality assur-
ance of these steps were also completed by a clinical and
methodological expert alternately, to ensure that all
included studies were extensively analysed and
appraised in accordance with both aspects. In the event
of disagreement, a consensus-building discussion was
envisaged identical to that used for the inclusion/
exclusion screening.yright © European Society of Anaesthesiology. UB3: Formulation and consensus building for
recommendations and statements
All Guideline authors were provided with the evidence
tables, the National Institute for Health and Care Excel-
lence (UK) checklists and the original publications, so as
to provide the authors with sufficient opportunity to
become familiar with the evidence base.
Formulation of recommendations and
statements
The authors of the corresponding chapters reviewed and
appraised the included studies assigned to their chapters,
and prepared these for presentation during the consensus
conferences. They also formulated preliminary recom-
mendations, including the Grade of Recommendation
(GoR), and statements. Recommendations offer gui-
dance for action with a direct topical link to the core
of the Guideline. Statements offer comment on or expla-
nation of specific circumstances or key issues without a
direct action being specified. Recommendations and
statements are adopted in the course of the formal
consensus procedure outlined below, and are based on
the available scientific evidence and expert opinion.
(http://leitlinienprogramm-onkologie.de/uploads/tx_
sbdownloader/LL_OvCA_OL_Langversion.pdf, (http://
www.krebsgesellschaft.de/download/s3-leitlinie-prostata
karzinom_2012.pdf).
The prepared evidence, preliminary recommendations,
including GoR and preliminary statements, were pre-
sented by the coordinators of the respective chapters in
the course of two consensus conferences (26–27 Septem-
ber 2013, 11–12November 2013) and discussedwith all of
the delegates. Position statements and recommended
alternative formulations were recorded by the conference
chairs.nauthorized reproduction of this article is prohibited.
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Table 4 Arbeitsgemeinschaft der Wissenschaftlichen
Medizinischen Fachgesellschaften wording schema to formulate
recommendations based on the strength of the recommendation
Grade of recommendation Strength of recommendation Wording
A Strong recommendation ‘must’
B Recommendation ‘should’
0 Open recommendation ‘may’
Source: http://www.awmf.org/leitlinien/awmf-regelwerk/ll-entwicklung/awmf-regel
werk-03-leitlinienentwicklung/ll-entwicklung-graduierung-der-empfehlungen.html.Consensus building
Using the Tele-Dialog system, an anonymous vote was
held on every statement and every recommendation,
including GoR. Where consensus could not be reached
there was further discussion followed by a final vote. The
classification of the degree of consensus is shown in
Table 3. Each specialist association attending received
one vote in the consensus process, regardless of the
number of delegates.
Grades of Recommendation
The Grades of Recommendation express the likelihood
that a relevant positive effect can be expected or a
negative effect can be avoided for the patient by follow-
ing the recommended course of action. The GoR
assigned by the Guideline authors takes into account
the methodological quality of the underlying studies
(LoE), the clinical relevance of the reported effective-
ness criteria and observed effect sizes, the consistency of
the study results, the transferability to the target popu-
lation, the applicability in routine medical practice,
ethical obligations and patient preferences. The relation-
ship between the LoE and the GoR, as well as the
modification of this mapping by the other factors men-
tioned, is indicated by the choice of terminology. In the
wording used to formulate the recommendations, the
terms ‘must’, ‘should’ and ‘may’ were associated with
GoR A, B and 0, to ensure the recommendation accu-
rately reflects the assigned GoR (Table 4).
B4 Dissemination and implementation
TheGuideline was disseminated by publication to online
media (AWMF website, links placed on websites of
participating medical societies), by presentations at
medical conferences [Deutsche Gesellschaft fu¨r Anaes-
thesiologie und Intensivmedizin (DGAI) Annual Con-
gress 2014 (preliminary presentation) 8–10 May 2014,
Deutsche Interdisziplina¨re Vereinigung fu¨r Intensiv- und
Notfallmedizin Annual Congress 3–5 December 2014,
DGAI Annual Congress 7–9 May 2015, Deutsche
Gesellschaft fu¨r Innere Medizin Annual Congress 18–
21 April 2015]. A manuscript summarising the key issues
was submitted to the scientific part of the Deutsches
Aerzteblatt (peer reviewed publication organ of the
medical profession in Germany)
The effects of implementation will be measured by
means of web-based questionnaire interviews using a
longitudinal design. The questionnaire was circulated
by the participating medical societies before the initialight © European Society of Anaesthesiology. Un
Table 3 Classification of degree of consensus
>95% agreement among participants Strong consensus
>75 to 95% agreement among participants Consensus
>50 to 75% agreement among participants Majority consensus
<50% agreement among participants No consensus
Source: http://www.awmf.org/leitlinien/awmf-regelwerk/ll-entwicklung/awmf-regel
werk-03-leitlinienentwicklung/ll-entwicklung-graduierung-der-empfehlungen.html.
Eur J Anaesthesiol 2016; 33:488–521publication and will be repeatedly circulated at regular
intervals thereafter.
A short version of the Guideline will also be published,
presenting the recommendations in a concise format.
Copies will be offered in A4 and A6 sizes – the latter
for use in the production of medical pocket cards. There
are also plans to develop smartphone applications, com-
patible with all of the popular operating systems.
B5: Quality indicators and evaluation
Volume therapy is used across an extraordinarily broad
spectrum of applications and clinical situations. Because
of this a change in treatment outcome because of the
Guideline cannot be measured by ‘hard’ outcomes such
as morbidity or mortality, as too many confounding
variables are involved. Guideline efficacy can be
measured meaningfully only in terms of process changes.
These are monitored by the repeat surveys conducted
during implementation research. The recommendations’
level of penetration into the knowledge of professional
groups addressed – particularly physicians – is applied as
a Guideline quality indicator. Review of implementation
in practice is possible in the form of audits or in the course
of peer reviews. No specific courses of action are planned
here.
B6: Validity and revisions
The Guideline was last revised on 18 June 2014. This
revision incorporated the comments made by the
specialist associations.
The Guideline is valid until 31 July 2017.
The Management Board of the DGAI will again ask the
participating specialist associations to appoint a delegate
to help in the revision of the Guideline, 1 year before the
validity period expires. The revision process will follow
the standard procedure as described above.B7: Funding and disclosure of possible conflicts
of interest
Funding to cover the costs of methodological support,
procurement of literature, organisation of the consensus
conferences and materials has been provided by the
DGAI. Attendee travel expenses were covered by
delegates themselves or the specialist associations they
represented.authorized reproduction of this article is prohibited.
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Intravascular volume therapy in adults 495At the beginning of each consensus conference, all
participants disclosed any potential conflict of interest.
In addition, all participants kept their conflicts of interest
up-to-date until the completion of their Guideline work.
A complete list of updated conflicts of interest statements
from all participants is given in the guideline report (http://
www.awmf.org/leitlinien/detail/ll/001-020.htmlpublished).
When necessary, an anonymous vote was held among
delegates of the specialist associations eligible to vote to
decide on the relevance of existing conflicts of interest. As
a result, no specialist association lost its vote in the con-
sensus process because of a conflict of interest affecting
its delegate.
Overall recommendations/statements:yInitial statement S-1right © European Society of AnaesthesioGoRFor lack of evidence, theoretically significant, differentiated recom-
mendations for fluid and volume therapy cannot be given with a
sufficient degree of certainty.
For this reason, the recommendations given for volume therapy are
also applicable to fluid therapy in cases of peri-interventional iso-
tonic dehydration.
All other forms of dehydration – especially in intensive care medi-
cine – require a differentiated approach to substitution. These
aspects do not form part of the GuidelineBackground to statement S-1
An intravascular volume deficit is characterised by hae-
modynamic instability, which occurs because of a critical
depletion of circulating plasma volume with a concurrent
drop in cardiac preload, reduction in cardiac output, and a
decrease in microcirculation and tissue oxygenation. This
is also accompanied by an interstitial fluid deficit. Accord-
ingly, the provision of adequate fluid and volume therapy
forms a very important part of the treatment of interstitial
fluid and intravascular volume depletion. The objective
of initial fluid and volume therapy is the restoration of
normal blood volume and a sufficient volume of circulat-
ing plasma, so as to ensure adequate venous return to the
heart and an appropriate cardiac output, increasing tissue
oxygenation and tissue perfusion and achieving improved
overall organ function.
In the extensive literature search conducted for this S3
Guideline on volume therapy in adult patients, with
17 898 abstracts screened for fulfilment of the inclusion
criteria, 762 screened full-text articles and 248 full-text
articles evaluated, no evidence could be found for the
above-mentioned recommendation made on pathophy-
siological grounds, as the existing scientific evidence
addresses itself to the problem of intravascular volume
depletion.
For this reason, and following in-depth discussion of
the relevant content, the Guideline group has decided
to make the overall recommendation that thelogy. Urecommendations given for volume therapy are also
applicable to fluid therapy in cases of isotonic dehy-
dration.
Furthermore, specific forms of dehydration such as
hypertonic dehydration are not dealt with, as these
specific forms of fluid and volume depletion would sig-
nificantly exceed the scope of the present Guideline.
Lastly, readers should also be aware that the EMA
convened a pharmacovigilance risk assessment in 2013
concerning the use of HES. The Pharmacovigilance Risk
Assessment Committee advises against use of HES in
patients suffering from sepsis and burns. HES can con-
tinue to be used to treat hypovolaemia following acute
blood loss. The recommendations of the present S3
Guideline are based on an analysis of the evidence and
are to be considered separately from the EMA recom-
mendations.nRecommendation O-1authorized reproduction of this article is 
Eur J Anaesthesiol 2016; 33:488–GoRIf rapid peri-interventional delivery of a volume substitute is required,
compressible bottles for rapid infusion should be used.BBackground to recommendation O-1
In the event of serious volume depletion combined with
life-threatening hypotension, the rapid restoration of
intravascular volume by forced volume substitution is
always indicated. In terms of equipment, compressible
containers for the required volume substitute offer a rapid
means of implementing this essential requirement in a
way that is decisive for survival. On the basis of this
clinically relevant approach, consensus was achieved for
the above recommendation despite the lack of scientific
evidence for this recommendation.
Applying the ‘patient population, intervention, compari-
tor, outcome’ principle, each key question is formulated
with consideration of the Patient population the guide-
line is made for, the Intervention and the respective
Comparator and the Outcome considered as relevant.
For this guideline, the intervention is defined by the
substance used, although it is incompletely characterised
without a description of themode of delivery. Indeed, the
importance of the mode of delivery in the context of
volume therapy can easily be understood merely by
considering the many clinical trials actively sought out
and thoroughly evaluated in many meta-analyses;4–6 in
some of these, volume substitutes were delivered over
several days, based on a twice-daily dosage regimen.7
In light of the above, it appeared prudent to promote a
rapid delivery option – especially in the event of a lack of
large-lumen intravenous access routes – so as to be able
to conduct volume therapy in the essential sense of the
term. Nevertheless, a comment was raised during theprohibited.
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496 Marx et al.consensus process to the effect that the acceptance of a
temporarily low level of blood pressure (BP) may, in
certain cases, be the advisable course of action (permiss-
ive hypotension).
Chapter 1: Diagnosis of hypovolaemia
Referenced literature:8–76i
ERecommendation 1-1ght © European Society of Anaesthesiolo
ur J Anaesthesiol 2016; 33:488–521GoREvery patient with a suspected volume deficit must be physically
examined, with especial attention to haemorrhage, dehydration and
other causes of volume loss. Their previous medical history must
also be consideredABackground to recommendation 1-1
One of the most basic decisions for maintenance of the
homeostasis of the human body is the choice of delivering
external solutions. The objectives at the heart of such
decision-making are the goals of volume substitution
(intravascular) and fluid substitution (interstitial). In
the majority of studies, the terms (intracellular) dehy-
dration and (extracellular) volume depletion are used
interchangeably, although defining two quite different
entities. In addition, posture-related syncope or reflex
tachycardia while standing (by over 30 beatsmin1) is
frequently indicative of a fluid volume deficit (hypovo-
laemia).77 In 1999, McGee et al. demonstrated that a dry
axilla, in contrast to moist mucous membranes, would also
increase the sensitivity for a diagnosis of hypovolaemia.
Interestingly, capillary refill time and skin turgidity
showed only very poor sensitivity, whereas presence of
tachycardia when lying down had only a high specificity.77
As every substance delivered to the body interacts with
the body’s own fluids in accordance with its composition,
stability and mode of delivery, predictions as to inertness
or the exchange of substances (down to the level of the
cell) are virtually impossible.
Total body water is held enclosed in various fluid spaces
(compartments): two-thirds are found in cells (intracellu-
lar compartment), whereas the remaining water is held in
the extracellular compartment and comprises interstitial
fluid (31%), blood plasma (7%) and other transcellular
fluid (cerebrospinal fluid, etc.). The body’s own regula-
tion of fluid balance is achieved by osmoregulation and
volume regulation, and the thirst reflex. The goal is to
maintain body water at a volume of approximately 42 l. As
the volume of the intracellular space is generally co-
controlled by the extracellular space (cell walls are
water-permeable), any fluid delivered to the body can
cause water displacement, down to the level of the cell.
As the interstitial fluid forms part of the extracellular
space and can be determined only indirectly as the
difference between overall extracellular space and
plasma volume, investigations of interstitial fluid deficitgy. Unare virtually impossible – at least without additional
instrument-based diagnostics. Accordingly, the sub-
stance-based substitution of the interstitial space is cer-
tainly neither advisable nor necessary. In the event of
isotonic hyperhydration, for example extended intravas-
cular volume delivery would result in an expansion of the
extracellular space with an increased incidence of inter-
stitial oedema because of diffusion.
The starting point for each further diagnostic step is a
thorough physical examination that can reliably estimate
the volume status while also estimating the response to
volume loading. Options available include inspection of
the tongue, jugular vein/dorsal venous network filling and
the nail blanch test. Alongside pulmonary auscultation
and percussion (for pleural effusion), abdominal palpa-
tion (ascites, distended intestinal loops) and inspection of
the lower extremities for dependent oedema and skin
turgidity are also necessary.
Saugel et al. in 2013, investigated the extent to which an
increase in the cardiac index by volume loading (’volume
responsiveness’, measured via transpulmonary thermo-
dilution) could be predicted from a clinical examination
performed by two independent practitioners. Apart from
the fact that these practitioners were in agreement for
about only half of the patients examined, the poor
positive predictive value of 27.8% illustrates the inaccur-
acy of clinical assessment.59 In 2011, the same group
achieved similarly poor results with another group of 71
internal medicine patients when applying the same
clinical tests (poor inter-observer agreement, low sensi-
tivity). Interestingly, hypovolaemia could almost always
be excluded, with a negative predictive value of 70%.60 In
summary, and in the context of differential diagnosis, we
may conclude that the rapidity and simplicity of the
physical examination means it must be performed on
every patient suspected to be suffering from a volume
deficit. Although the physical examination alone cer-
tainly fails to satisfy the requirements of comprehensive-
ness, it considerably improves diagnostic quality when
combined with further tests.Recommendation 1-2authorized reproduction of this article is pGoRTo diagnose a volume deficit, data on laboratory variables such as
lactate, central venous oxygen saturation, haematocrit or base
excess must also be consideredABackground to recommendation 1-2
In recent years the collection of data on a host of labora-
tory variables, some redundant, has become established
as a standard procedure on patient admittance. As a
result, clinical assessment of the patient and the associ-
ated diagnostic expertise has been increasingly oversha-
dowed, and is on occasion reduced to merely waiting for
the laboratory results before even daring to make arohibited.
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of critical volume depletion shock, waiting for laboratory
results is a pointless and often fatal exercise. Here,
prompt clinical assessment is sufficient, combined with
a medical history to identify the right treatment.
Notwithstanding the above, a handful of laboratory
variables are important in the differential diagnosis of
hypovolaemia, such as the determination of the urea-to-
creatinine ratio to estimate volume loss, or hypernatrae-
mia (in advanced dehydration), and should not be
omitted.
Recently, attention has been increasingly directed
toward the determination of the base excess following
acid-base disturbances caused by tissue hypoxia or
underperfusion following serious trauma, with volume
depletion because of exsanguination or trauma-induced
coagulopathy, as this facilitates an estimation of prog-
nosis. In addition, lactate is a marker of anaerobic metab-
olism which is useful to assess ischemic tissue damage in
extremities and vital organs. The determination of
mixed venous (or simply central venous) oxygen satur-
ation as a marker for the desaturation of erythrocytes and
thus the systemic oxygen consumption (VO2) has now
become established as the standard for intensive care
medical services.
All laboratory variables can be used for monitoring, i.e.
the measurements can be repeated at fixed intervals.
This allows to detect improvement or worsening of
the patient, or enables to estimate the prognosis, for
example by considering lactate values in the treatment
of sepsis.
In 2010, Futier et al.33 demonstrated that a decrease in
central venous oxygen saturation (ScvO2) with restrictive
volume therapy, seen in 70 visceral surgery patients
intraoperatively, and confirmed in the multivariate
analysis, was a predictor for postoperative sepsis or ana-
stomotic insufficiency. In 2013, Saugel et al.59 recorded a
negative predictive value and a specificity of just under
71% for ScvO2, with a threshold of under 70%, for the
diagnosis of hypovolaemia in 38 internal medicine
patients. This threshold of 70%, familiar from sepsis
guidelines, was investigated by Monnet et al. as a surro-
gatemarker for elevated oxygen consumption in 51 septic
internal medicine patients. In contrast to lactate [area
under the curve; usually this applies to the receiver
operating characteristic (ROC) curve (AUC) 0.91 and a
sensitivity of 93% with a cut-off of 2.77mmol l1], ScvO2
achieved an AUC value of only 0.68 and was therefore a
poorer marker for the increase in VO2 (except for a value
of under 50%). Interestingly, oxygen delivery decreased
in the nonresponders, probably because of dilution
and thus a reduced haemoglobin value. This, in turn,
demonstrates that a ‘fluid challenge’ should be seen as a
one-time attempt in the event of surrogate markers
remaining unchanged.49yright © European Society of Anaesthesiology. UnRecommendation 1-3authorized reproduction of this article is 
Eur J Anaesthesiol 2016; 33:488–GoRCentral venous pressure must not be used to diagnose a volume
deficit in spontaneously breathing or ventilated patients: this pro-
hibition applies to both perioperative and intensive care patientsAThe Management Board of the German Sepsis Society (DSG) commented on
this recommendation in the scope of the external appraisal as follows: the DSG
cannot consent to this recommendation, as relevant prognostic studies are
unavailable and the ratio of benefits to risks for this Grade A recommendation is
unbalanced (’undesirable probably outweighs desirable’).
Background to recommendation 1-3
For a long time, central venous pressure (CVP) formed
part of basic routine monitoring for critically ill patients.
Over the past few years, studies with various patient
groups have shown repeatedly that the correlation of
changes in CVP and pulmonary artery occlusion pressure
with changes in cardiac output is at best very poor and at
worst entirely absent, and that the measurement of the
CVP has only minimal predictive power in determining
the status of intravascular volume. The underlying reason
for this is that CVP is dependent on a broad spectrum of
factors, including intravascular volume, peripheral vas-
cular tone, right ventricular compliance, pulmonary vas-
cular resistance and intrathoracic pressure (in ventilated
patients). Although low CVP may indeed indicate a
volume deficit, elevated CVP is equally unable to
exclude the presence of volume depletion. By way of
illustration, an elevated CVP is possible in the event of
right-sided heart failure, pulmonary embolism, cardiac
tamponade, tension pneumothorax or hypervolaemia. In
amuch-cited study on early goal-oriented sepsis therapy,
Rivers et al. were able to demonstrate a significant
reduction in mortality by specifying a CVP target value
between 8 and 12mmHg. It should be noted that CVP in
this study was utilised only as part of a pool of multiple
haemodynamic target criteria. Accordingly, isolated
evaluation of CVP in the context of this study is not
possible.78
In a prospective observational study in patients with
septic shock (n¼ 25), CVP, shock index and cardiac index
were measured with transthoracic echocardiography
immediately before and after a volume bolus.39 Haemo-
dynamic response was defined as an increase in the
cardiac index of at least 15%. Patients with CVP more
than 8mmHg and a lowered shock index did not benefit
from volume loading. Yet with both lower CVP
(<8mmHg) and higher shock index it was still not
possible to reliably predict volume responsiveness.
In a prospective study with 31 medical ICU patients,
Saugel et al.59 investigated the extent to which clinical
examination, CVP, passive leg raising, ScvO2 or trans-
pulmonary thermodilution were able to predict volume
responsiveness. All variables investigated, including that
of CVP, demonstrated inadequate reliability in this
study.prohibited.
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498 Marx et al.In a recent meta-analysis,79 CVP was investigated in
terms of its capacity to predict volume responsiveness.
A total of 43 studies were included in the analysis. Of
these, 22 studies concerned intensive care patients, 20
analysed CVP within operative monitoring and one study
was conducted with study participants. Volume respon-
siveness was equated with an increase in cardiac output or
stroke volume following a defined volume loading pro-
cedure (volume challenge) or after passive leg raising
(PLR).Most studies defined volume responsiveness as an
increase in the cardiac index or stroke volume index by
over 15%. The volume challenge constituted the intra-
venous delivery of 500ml of fluid (usually HES). Data for
the receiver operating characteristic curve were available
in 20 studies. Overall, 57 13% of patients were volume-
responsive. Average CVP as initially measured was
8.2 2.3mmHg in the volume-responsive group and
9.5 2.2mmHg in nonvolume-responsive patients.
The AUC value for the ROC curve was 0.56 [95%
confidence interval (95%CI) 0.54 to 0.58]. No difference
was seen between intensive care and operating
theatre patients. The same results were also obtained
for cardiac surgery and noncardiac surgery patients. In
all groups, correlation of the initial CVP measurement
with the change in cardiac index and stroke volume
was poor.
In conclusion, the measured filling pressure cannot be
used to draw reliable conclusions about a specific volume
status. It is also subject to numerous factors that interfere
with interpretation.
Existing guidelines:
The S3 guideline ‘Post-infarction cardiogenic shock:
diagnosis, monitoring and therapy’ includes the state-
ment that CVP should not be used as a guide for volume
management. (http://www.awmf.org/leitlinien/detail/ll/
019-013.html).
The S3 guideline ‘Provision of intensive care medicine to
cardiosurgical patients: haemodynamic monitoring and
cardiovascular therapy’ cites the limited usefulness of
CVP in relation to volume management. The guideline
nonetheless mentions the option of continuous measure-
ment as a means of obtaining important information
about acute changes in right ventricular compliance
and/or volume status. (http://www.awmf.org/leitlinien/
detail/ll/001-016.html).
The Surviving Sepsis Campaign ‘Guidelines for manage-
ment of severe sepsis and septic shock’80 recommend
CVP measurement in sepsis with signs of hypoperfusion
with a target value of 8 to 12mmHg in the first 6 h (grade
1C). The German S2k sepsis guideline81 also recom-
mends a CVP goal of more than 8 and 12mmHg with
mechanical ventilation as part of a pool of haemodynamic
target criteria for early haemodynamic stabilisation (grade
of recommendation C).ight © European Society of Anaesthesiology. Un
Eur J Anaesthesiol 2016; 33:488–521Recommendations 1-4, 1-5, 1-6authorized reproduction of this article is pGoRIf feasible, a positional manoeuvre facilitating autotransfusion (Tren-
delenburg position, passive leg raising) should be performed to
diagnose a volume deficit/volume responsivenessBIdeally, stroke volume or a dynamic preload variable should be
measured to investigate volume responsivenessBA change in BP may be used for an initial evaluation of volume
responsiveness0Common background to recommendations 1-4,
1-5, 1-6
With no major requirements in terms of equipment,
PLR is an easily performed bedside examination for
diagnosing volume depletion in addition to potential
volume responsiveness. The manoeuvre results in a
reversible autotransfusion of 300 to 450ml. By increas-
ing cardiac preload (in the case of a volume-depleted
patient), the stroke volume can be increased (assuming
peripheral resistance remains unchanged), and thus
cardiac output, for the duration of the test. Use of
the PLR manoeuvre can also avoid the
often harmful excess volume resulting from frequent
infusion boli with suspected hypovolaemia; rates of
pulmonary oedema and perfusion disorders can also
be reduced.
However, a standardised PLR manoeuvre in hospital
presents considerable problems: the upper body may
be inappropriately positioned, or an above-knee amputa-
tion may be present or there may be congestive
heart failure.
In a prospective clinical trial with 39 intensive care
patients receiving interdisciplinary treatment, Boulain
et al.82 (2002) achieved a good correlation between
increased stroke volume and a directly proportional rise
in aortic pulse pressure, verifying the positive effects of
simulated volume loading.
In 2002 meta-analysis that included a total of 9 studies
and 353 participants (intensive care patients with shock
because of a range of factors), Cavallaro et al. reported the
reliability of the predictive power of PLR in relation to an
increase in cardiac output and stroke volume (as deter-
mined via pulmonary catheter, transoesophageal echo-
cardiography (TEE)/transthoracic echocardiography
(TTE), transpulmonary thermodilution and uncalibrated
pulse contour analysis). Despite variations in the per-
formance of the PLR manoeuvre (from a supine or half-
sitting position) and a range of definitions of responders,
cumulated sensitivity was 89.4% with a specificity of
91.4% in relation to an increase in cardiac output
(AUC 0.95). The measured rise in pulse pressure results
in a sensitivity of only 59.5% with a specificity of 86.2%
(AUC 0.76).12
Mandeville et al. performed a systematic review that
considered eight studies using TTE to compare volume
responsiveness, and showed that the PLR manoeuvrerohibited.
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sensitivity of 100% in relation to stroke volume, stroke
volume index and cardiac output. The positive predic-
tive value fluctuated between 83 and 91%, with the
volumes compared varying between 500ml colloid and
crystalloid. Included in this review was the cross-sec-
tional study from Biais et al.,10 in which stroke volume
was measured via TTE or the uncalibrated pulse con-
tour analysis technique (software version 1.14) in 30
patients (19 intubated and spontaneously breathing).
Here, too, the PLR manoeuvre (compared to 500ml
saline solution) was able to predict volume responsive-
ness in a reliable manner (compared to the uncalibrated
pulse contour analysis, AUC 0.92). Better results were
returned by the comparative TTE measurement (AUC
0.96).43
In the cross-sectional study from Lakhal et al. with 112
patients (ventilated, haemodynamically unstable, of
which 21 were arrhythmic), volume responsiveness was
investigated using noninvasive/invasive BP increases
(systolic and mean pressures) induced by PLR (458)
compared to invasive cardiac output measurement as
the reference measure. The change in SBP was also
significant (AUC 0.75) even for the noninvasive BP
measurement. With the application of an additional arbi-
trarily chosen CVP increase of at least 2mmHg, the AUC
rose to 0.94. Qualitatively, however, the data are very
hard to interpret, as the specification of the reference test
was nonuniform and specification of the CVP criterion
was arbitrary.83
In 34 spontaneously breathing, hypotensive internal
medicine patients, Maizel et al. validated the echocardio-
graphically determined volume responsiveness of car-
diac output and stroke volume via PLR or 500ml saline
solution (with noninvasive BP measurement). None-
theless, the authors state in their final conclusions that,
while the PLR manoeuvre has good predictive power,
the poor quality of reporting and conflicting sets of
results mean the statement must be treated with cau-
tion.42
Preau et al. used a different PLR manoeuvre for 34
spontaneously breathing septic patients. This passive
leg-raising manoeuvre also involved lowering the upper
body, thus simulating a larger volume bolus (of about 450
to 500ml, in comparison to 500ml 6% HES). Both the
change in stroke volume and radial pulse pressure
demonstrated good predictive power (AUC of 0.94 and
0.86, respectively).55
Dong et al. compared the change in indexed stroke
volume with transpulmonary thermodilution measure-
ment following the same PLR manoeuvre as Preau in
32 septic and ventilated internal medicine patients.
Interestingly, with a cut-off of around 9%, the same
sensitivity (72.7%) and specificity (80%) were seen as
for a CVP change of at least 12.7%. The AUC was 0.882yright © European Society of Anaesthesiology. Ufor the change in stroke volume, whereas the CVP
increase achieved an AUC of 0.805.25
In the course of performing the PLR manoeuvre in 65
septic internal medicine patients on continuous manda-
tory ventilation, Monnet et al. interestingly chose to use
end-tidal carbon dioxide measurement as a surrogate
marker for volume responsiveness rather than measuring
cardiac ouput via transpulmonary thermodilution.
Despite methodological deficiencies, AUC was shown
to be 0.93 with a specificity of 100% (sensitivity 71%) for a
cut-off of 5%. The AUC for measurement of cardiac
output was 0.98. The authors conclude that if extended
haemodynamic monitoring is not available, carbon diox-
ide measurement offers a suitable alternative.47
In conclusion, a positive PLR manoeuvre (rising arterial
pulse pressure) can be used to provide a guideline esti-
mate of the effect of volume loading on stroke volume or
cardiac output, and thus be of assistance in resolving
potential therapeutic conflicts.
In spontaneously breathing patients, however, one must
remember the risk of aspiration, especially with visceral
surgery patients. Nor should themanoeuvre be applied in
the presence of cardiogenic shock, intracranial bleeding
or elevated cerebral pressure.
No data are available for patients with elevated intra-
abdominal pressure.
If extended haemodynamic monitoring is available (car-
diac output/stroke volume measurement), then this
should be used preferentially with a threshold between
8 and 15%. The correlation rises with the use of extended
haemodynamic monitoring. Neither ventilation nor
arrhythmias were relevant factors affecting the results.
In the case of basic monitoring, the (radial) pulse pressure
(SBPDBP) can be used – a positive prediction equates
to an elevation of at least 9 to 12%.nRecommendation 1-7authorized reproduction of this article is 
Eur J Anaesthesiol 2016; 33:488–GoRVolumetric preload indices (intra-thoracic blood volume or global
end-diastolic volume) may be used to diagnose a volume deficit0Background to recommendation 1-7
Volumetric preload indices can be determined using
transpulmonary thermodilution. The cardiac ouput
measured using thermodilution is multiplied together
with the mean transit time and downslope time of the
transpulmonary temperature-time curve to calculate the
intra-thoracic thermal volume (ITTV) (ITTV¼ cardiac
output  mean transit time) and the pulmonary thermal
volume (PTV) (PTV¼ cardiac output downslope time);
the difference defines the global end-diastolic volume
(GEDV¼ ITTVPTV).The intra-thoracic blood volume
(ITBV) is calculated from the GEDV using an empirically
determined correction factor (ITBV¼ 1.25GEDV).prohibited.
521
Copyr
500 Marx et al.The measurement requires the use of a specialised
monitor and a cold fluid – generally 20ml per indicator
injection. To reduce the measurement’s coefficient of
variation, multiple indicator injections are typically per-
formed at each time of measurement.84,85 Measurement
can be performed in a largely standardised manner. Com-
mon errors such as inadequate injectate volume or exces-
sively warm injectate are shown on the monitor, enabling
the avoidance of typical causes of signal-to-noise ratios that
are too low.
Multiple small cross-sectional studies were analysed to
assess the value of volumetric variables as volume respon-
siveness predictors. The reference test used was the
increase in thermodilution cardiac output or thermodilu-
tion stroke volume for defined volume loading, whereby
separate threshold values were applied for the diagnosis
of a volume deficit.
De Waal et al. investigated 22 patients during elective
coronary bypass operations and defined volume respon-
siveness as a rise in stroke volume (thermodilution
measurement) of at least 12% by an infusion of 6%
HES 10ml kg1 BW. ROC analysis showed that indexed
values of GEDV and ITBV were unable to predict
volume responsiveness (AUC (95% CI) for GEDVI:
0.700 (0.460; 0.940); for ITBVI: 0.682 (0.441; 0.923),
regardless of whether the thorax was opened (AUC value
for ROC curve (95% CI): 0.756 (0.500; 1.011) for both) or
closed.23
Hofer et al. investigated 40 patients during ‘off-pump’
coronary revascularisation, finding that GEDVI and
ITBVI were unable to predict the volume responsiveness
of stroke volume measured via thermodilution, with an
AUC value for the ROC curve of 0.493 (95% CI: 0.292;
0.688). Of note, Hofer et al.35 used the unusually high
threshold value of at least 25% as the diagnostic criterion
for volume responsiveness.
In 32 ICU patients after major vascular interventions or
coronary surgery, Trof et al. were able to show that the
diagnostic quality of GEDVI is dependent on cardiac
function. The global ejection fraction (GEF¼ 0.25 -
stroke volume/GEDVI) was used for patient stratifica-
tion. Where GEF at least 20%, volume responsiveness
was predicted by considering the GEDVI. The AUC
value was 0.72 (0.58; 0.83) or 0.89 (0.78; 0.95) depending
on the threshold used for the rise in cardiac index (see
below). Where GEF is less than 20%, however, the
corresponding confidence intervals encompassed the
value 0.5 for both threshold values. Cardiac index
increases of at least 10 and 15% were analysed as
threshold values for volume responsiveness. The AUC
value was higher in both patient groups, however, when
the higher threshold was applied. For patients with a
GEF at least 20%, sensitivity, specificity and the positive
and negative predictive values for the rise in cardiac
index of at least 10% were 82, 56, 42 and 89%,ight © European Society of Anaesthesiology. Un
Eur J Anaesthesiol 2016; 33:488–521respectively; the GEDVI diagnostic threshold for volume
responsiveness was 890mlm2. For the cardiac index rise
of at least 15%, the corresponding values were 71, 94, 63
and 93%, and the GEDVI threshold value was
623mlm2.65
Huang et al. investigated volume responsiveness in 22
patients experiencing early-stage ARDS. The AUC value
for the ROC curve was the same for both GEDVI and
ITBVI at 0.323. Accordingly, the suitability of both
values for the diagnosis of volume depletion in ARDS
patients could not be confirmed.36
Indirect indications of the suitability of ITBVI for diag-
nosing a volume deficit come from the findings of a study
from Molnar et al. Using HES and gelatin infusion with
the goal of boosting ITBVI to more than 900mlm2, they
were able to significantly improve oxygen delivery index
(DO2) independently of the colloid used.
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Szakmany et al. compared an ITBVI-based volume
therapy with one that was CVP-based in patients during
elective major visceral surgical intervention, and found a
weak but significant correlation of the ITBVI with the
changes in the stroke volume index. No data on diag-
nostic quality can be derived from this study, however.87
In summary, on the basis of the data as presented here,
the suitability of volumetric measurements in the diag-
nosis of a volume deficit is limited. All of the studies cited
involved small cohorts and exhibit a low level of meth-
odological quality. Notwithstanding the above, the S3
guideline ‘Provision of intensive care medicine to cardi-
osurgical patients: haemodynamic monitoring and cardi-
ovascular therapy’ considers that volumetric analysis is
superior to CVP and pulmonary artery occlusion pressure
(PAOP) in terms of estimating cardiac preload.88 The
apparent discrepancy between these two guidelines can
be traced to the different research strategies used.
Further, it is clear that because disparity existed between
the key issues considered by these two guidelines, the
research that went into the ‘Provision of intensive care
medicine to cardiosurgical patients’ guideline was more
detailed than was achievable for the present Guideline.
Nor did research into the present Guideline involve any
background investigation limited to specific patient
groups. The narrow scope of the evidence available to
us does not permit endorsement in relation to the suit-
ability of volumetric procedures for the diagnosis of
volume depletion. For this reason, the Guideline Group
recommends that volumetric variables are given the low-
est grade of recommendation.Recommendation 1-8authorized reproduction of this article is pGoRThe ventilation-induced variation of the stroke volume (measure-
ment of dynamic preload) should be used to diagnose volume
deficit and volume responsivenessBrohibited.
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The commonest motivation for delivering a fluid bolus to
a patient is to increase stroke volume and cardiac output
with a concomitant improvement in oxygen delivery –
insofar as the patient is located on the ascending portion
of the Frank-Starling curve. If not, the volume loading
would have little beneficial influence on the cardiac
output and actually produce an opposite and negative
effect. In this light, establishing potential volume respon-
siveness is essential for patient care.
In recent years, a number of dynamic measurements
based on changes to the pulse curve have emerged. Pulse
pressure variation and systolic pressure variation are
derived from the analysis of the arterial waveform,
whereas stroke volume variation is taken from pulse
contour analysis. Several methods of pulse contour
analysis are available. One uses arterial pulse contour
analysis and transpulmonary thermodilution to plot the
proximally derived arterial pressure waveform against
the stroke volume of the heart. Following calibration of
the pulse contour analysis continuous estimates are made
of a series of values, including stroke volume variation
(SVV) and pulse pressure variation (PPVar) as additional
indices of preload, and overall systemic resistance from
stroke to stroke. Recalibrationmay be necessary every 4 to
8 h or after changes to individual vascular compliance.
The uncalibrated pulse contour analysis is based on the
analysis of the arterial pressure waveform, combined with
an individual calibration factor (x), which depends on
patient criteria (arterial compliance depends on age, sex
and body surface area) and is dependent on the charac-
teristics of the arterial waveform (slope and kurtosis,
determined by peripheral resistance). Cardiac output
and stroke volume are calculated using the formula
CO ¼ heart rate  SV ðpulsatility  xÞ
‘Pulsatility’ is the standard deviation of the arterial pres-
sure waveform over a specified period.
The equation is based on a database consisting of arterial
pressure waveforms and cardiac output reference values
from thermodilution calculations. Initial versions of the
software encountered major problems in achieving
reliable calculation of cardiac output (because of a lack
of human data). From version 1.10, however, the cali-
bration factor x is calculated from a larger database and
updated every minute (second software generation). The
third generation (from v. 3.0) of the uncalibrated pro-
cedure for pulse contour analysis compares the x variable
every minute with an even larger database, which con-
tains more data from hyperdynamic patients with severe
vasodilation, and is updated every 20 s.
Uncalibrated pulse contour analysis appears to be in
broad agreement with the thermodilution method
and cardiac output determined by echocardiographicyright © European Society of Anaesthesiology. Umeasurement. Studies making direct comparisons
between the methods are uncommon and are all from
the field of cardiac surgery. Here, however, divergent
results with occasionally low correlation coefficients are
found. Accordingly, conclusive assessment as a sole refer-
ence value is difficult. Overall, transpulmonary thermo-
dilution seems to achieve a better predictive value than
uncalibrated pulse contour analysis.76
Physiologically, pulse contour analysis is based on the
change in the pulse wave in monitored ventilation with
intermittent fluctuations in biventricular preload, which
responds differently to inspiration and expiration in
accordance with the volume status. This leads to signifi-
cant variation in systolic pressure variation (SPV);
the greater the tidal volume, the better the potential
evaluation (at least 8ml kgBW1). Spontaneous venti-
lation permits only very limited use of the calculated
values.52
Unlike PPVar and SVV, however, SPV is often deter-
mined manually and this produces less reliable results
than values calculated digitally in real time. The latter
provide the typical characteristics of SPV.
Normally, the threshold value for volume responsiveness
is located between 11 and 13% for all variables. Although
slightly reduced cardiac output (ejection fraction <40%)
would not adversely influence the soundness of the
variables, arrhythmias, more serious valve defects and
intracardiac shunts lessen the reliability of the measure-
ments. High doses of vasopressors can also work to
change arterial compliance.
Khwannimit et al. investigated 42 septic internal medi-
cine patients on continuous mandatory ventilation using
the third generation of the software (v. 3.01) for uncali-
brated pulse contour analysis, to calculate SVV as a
predictor for volume responsiveness. With a cut-off value
of 10%, the AUC (0.92) was comparable with the calcu-
lated PPVar, a procedure based on mathematical analysis.
With a cut-off value of 12%, PPVar achieved almost the
same AUC (0.916) with P< 0.001.37 Cannesson et al.
investigated 25 ventilated cardiosurgical patients to
determine the predictive power of SVV, PPVar and
cardiac index. Although a similar AUC value was found
for PPVar and SVV (namely 0.871 and 0.857), values of
only 0.298 and 0.533 were found for cardiac index and
CVP. Interestingly, Cannesson took the view that,
despite the different software algorithms used to deter-
mine SVV, the fluctuations nonetheless exhibited very
good correlation with the volume status, regardless of the
errors made in calculating stroke volume and cardiac
output, as they were naturally related to the correspond-
ing pulse contour analysis.11
In a systematic review of 568 patients, Zhang et al.
measured an AUC of 0.84 for SVV with a sensitivity of
81% and a specificity of 80%, with the average cut-offnauthorized reproduction of this article is prohibited.
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502 Marx et al.value lying at approximately 10%. This review was
adversely affected by pronounced heterogeneity of the
studies included.76
Suehiro et al. compared two separate tidal volumes in 73
patients receiving one-lung ventilation to determine the
predictive power (in relation to volume demand) of SVV
using uncalibrated pulse contour analysis. With a tidal
volume of 8ml kgBW1, the cut-off of 10% achieved an
AUC of 0.776 with a sensitivity of 85.7% and a specificity
of 66.7%. In the second group, with a tidal volume of
6ml kgBW1, an even lower cut-off of 8% was unable to
achieve a sufficient level of statistical quality. A possible
cause could be the smaller difference in transpulmonary
or pleural pressure.64 In 2010, the same group also inves-
tigated 30 patients on one-lung ventilation, calculating a
SVV of 10.5% with an AUC of 0.90 as an optimum
predictive value. Yet the study data themselves were
highly incoherent and inadequately validated.63
Yang et al. investigating 79 patients having elective
surgery achieved a good correlation for PPVar compared
with corrected aortic flow time measured with transoe-
sophageal cardiography). The AUC value was 0.935 (cut-
off 15%); the value for corrected aortic flow time (FTc)
was 0.822. Conspicuous was the significantly (P¼ 0.014)
improved predictive power of PPVar in the prone position
(AUC 0.969) compared to FTc (AUC 0.846).73 Yazigi et al.
investigated 60 cardiosurgical patients to compare PPVar
with CVP and PAOP as a predictor of volume expansion
with HES 7ml kgBW1. Neither CVP (0.43) nor PAOP
(0.42) achieved the AUC value for PPVar (0.85, cut-off
11.5%), measured in terms of stroke volume change using
pulmonary artery catheterisation.74
Shin et al. investigated 33 liver transplants during
the anhepatic phase to determine the predictive power
of CVP, PAOP and femoral SVV (uncalibrated pulse
contour analysis). With a cut-off value of 8%, a sensi-
tivity of 89% was achieved with a specificity of
80%; the value for AUC was 0.894 compared to
0.576 (CVP) and 0.67 (PAOP). The authors state that
the cut-off of 8% represents a negligible difference to
the calibrated pulse contour analysis with a cut-off of
9.5%, further noting that, especially in hypotonic
patients, aortic pressure can be underestimated when
BP is measured in the radial artery – although no
relevant differences were found in either of the two
measurements.61
The reduced predictive power of SVV (with calibrated
pulse contour analysis) in 30 intubated but spon-
taneously breathing septic patients was made abun-
dantly clear by Perner et al. Here, the multivariate
analysis was unable to yield an adequate AUC value
(0.52 to 0.64) for stroke volume variation. Probable
options for improvement would be the extension of
the 30-s SVV averaging or the calculation of SVV within
a single respiratory cycle.52ight © European Society of Anaesthesiology. Un
Eur J Anaesthesiol 2016; 33:488–521Recommendation 1-9authorized reproduction of this article is pGoRTo examine the volume status in ICU patients transthoracic
echocardiography may be used.0Background to recommendation 1-9
TTE has the advantages of being readily available and
noninvasive. Its disadvantages are that the procedure
is strongly investigator-dependent and cannot be
deployed as a continuous procedure. In principle, the
semi-quantitative filling state of the right and left
ventricles can be used to draw conclusions about the
volume status. However, probing inaccuracies translate
to imprecision in the indices that determine hypovo-
laemia.89 A volume deficit can be safely assumed in the
event of ventricles walls coming together (‘kissing
ventricles’).
In a systematic review, Mandeville et al. identified
eight studies that investigated TTE in relation to
preload and volume responsiveness. The authors ident-
ified a good differentiation between volume responders
and nonresponders using TTE. Unfortunately the pro-
nounced heterogeneity of the studies (including the
different TTE-based techniques) ruled out the per-
formance of a meta-analysis. In addition, a majority of
nonventilated patients were investigated with thermo-
dilution techniques without comparison.43 A recent
systematic review by Wetterslev et al.90 was unable
to identify any study that compared TTE with cardiac
output or stroke volume measured invasively via pul-
monary arterial catheterisation or transpulmonary ther-
modilution, in the context of diagnosing a volume
deficit.
Existing guidelines:
The American Heart Association classifies the deploy-
ment of TTE in assessing volume status for critically-ill
patients as ‘Uncertain’, with a medium grade of recom-
mendation (U5).91Recommendation 1-10 GoREchocardiography must be performed on patients exhibiting unclear
haemodynamic instability (particularly in cases where a cardiac
cause is suspected).ABackground on recommendation 1-10
In patients exhibiting unclear haemodynamic instability,
echocardiography can be used to distinguish between a
wide range of differential diagnoses such as pericardial
effusion and tamponade, acute right heart strain as an
indicator of pulmonary arterial embolism, restricted
pump function, valve defects and others. For cardiogenic
shock in particular, TTE andTEE are an essential part of
the diagnostic armoury.92rohibited.
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The American Heart Association classifies the deploy-
ment of TTE in patients with hypotension or an unclear
case of haemodynamic instability as ‘Appropriate’, with
the highest grade of recommendation (A9).91
The S3 guideline ‘Treatment of multiple trauma/
seriously-injured patients’ states that echocardiography
should be performed in haemodynamically unstable
patients with multiple traumas for the diagnosis of peri-
cardial tamponade or rupture. The guideline recom-
mends TTE as the method of choice. (http://www.
awmf.org/leitlinien/detail/ll/012-019.html).
The S3 guideline ‘Postinfarction cardiogenic shock: diag-
nosis, monitoring and therapy’ states that TTE is essen-
tial for patients with post-infarction cardiogenic shock
and should be performed as soon as possible following
patient admission. Data obtained by echocardiography
helps to assess the global and regional pump and valve
function of the left and right ventricle, and to detect acute
complications of a myocardial infarction, such as free wall
rupture, ventricular septal defect or papillary muscle
rupture. (http://www.awmf.org/leitlinien/detail/ll/019-013.
html).
The S3 guideline ‘Provision of intensive care medicine to
cardiosurgical patients: haemodynamic monitoring and
cardiovascular therapy’ recommends echocardiography to
confirm diagnosis in the perioperative period for patients
exhibiting acute and sustained haemodynamic disorders
who do not respond to initial treatment, and for those
whose ventricular function and its determinants are
unclear. The guideline recommends this as a prudent
step that improves the clinical outcome (GoR B). (http://
www.awmf.org/leitlinien/detail/ll/001-016.html).yRecommendation 1-11right © European Society of AnaesthesioGoRA sonographic measurement of the inferior vena cava (IVC) may be
performed on ICU patients to diagnose a volume deficit0Background to recommendation 1-11
As a general rule, bedside determination of the size of the
IVC directly underneath the diaphragm can help to
diagnose hypervolaemia or hypovolaemia.8,21,28 The
diameter of the IVC is influenced by the respiratory
cycle, blood volume and right heart function. It must
be remembered that sonographic determination of the
size of the vena cava is an indirect indicator of CVP and is
thus subject to the same limitations.
In a study investigating 20 septic ventilated ICU patients,
responders and nonresponders were classified according
to cardiac output increase following a volume bolus.20 In
contrast to CVP, a vena cava distensibility index (respir-
atory change of IVC diameter/minimumdiameter of IVC)logy. Uof 18% was able to differentiate responders and nonre-
sponders with a sensitivity and specificity of 90%.
Most of the older studies were conducted on ventilated
patients with sepsis but a meta-analysis published in
2012 identified five prospective studies that investi-
gated the diameter of the IVC in assessment of volume
status in spontaneously breathing patients. For hypo-
volaemic patients, the maximum diameter of the vein
was significantly smaller than in those who were euvo-
laemic (average difference; 95% CI 6.3mm, 6.0 to
6.5mm).93
Overall, there is a moderate body of evidence suggesting
that the vein has a smaller diameter in hypovolaemia than
with euvolaemia but there are no major multicentre
studies that examine this key issue. Sonography of the
vena cava is a simple procedure that can be performed
rapidly and noninvasively. The examination can be com-
bined with TTE. Although the present studies vary in
terms of their diagnostic threshold values, the following
values can be given as a general reference:
IVC diameter less than 10mm¼hypovolaemia likely
IVC diameter more than 22mm¼hypervolaemia
likely (other causes also possible).
Hypovolaemia is also frequently indicated by strong
variation in the vein diameter over the respiratory cycle.
Chapter 2: Therapy during the fasting phase
Referenced literature:94–97nStatement S-2authorized reproduction of this article is 
Eur J Anaesthesiol 2016; 33:488–GoRBased on the available data, no statement concerning the effect of
volume therapy in the fasting stage can be made with regard to
survival—Background to statement S-2
In recent years, interest in the fast-track model has
greatly increased attention on volume therapy in the
pre-interventional fasting phase. Despite this, the sys-
tematic literature search conducted for the present
Guideline discovered only a few studies of its use in
fast-track surgery. Accordingly, an evidence-based
assessment of volume therapy in the fasting phase is
not possible on the basis of the publications referenced
here. Note that the above statement does not contradict
the positive results obtained by the fast-track model. The
scope of the fast-track model encompasses much more
than preoperative fluid therapy, however, and the effects
of fluid therapy have not been investigated separately. In
the context of the present Guideline, therefore, the
correct methodological approach is to derive no recom-
mendations on preinterventional fluid therapy from these
studies.prohibited.
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ERecommendation 2-1ght © European Society of Anaesthesiolo
ur J Anaesthesiol 2016; 33:488–521GoRAny volume deficit existing before intervention should be compen-
sated for before interventionBBackground to recommendation 2-1
As already discussed above, it is virtually impossible to
derive evidence-based statements on preoperative fluid
therapy from the systematic literature search for this
Guideline. No direct evidence of the effects on mortality
is available.52 Isolated data supporting a lower postopera-
tive nausea and vomiting rate because of preoperative
fluid substitution,94 a lesser degree of dehydration during
preoperative bowel preparation,97 and assessments of
liver blood flow and other haemodynamic variables95
are found in the literature but do not favour a strong
recommendation.
However, it seems eminently reasonable to state that
existing deficits should be rectified promptly; preinter-
ventional fluid therapy is considered prudent in the event
of preinterventional deficit. In this context one must
consider that all studies on goal-oriented haemodynamic
therapy, preload optimisation via PLR, or volume expan-
sion, ultimately aim to compensate for a difference
between the actual state and an optimum state – the
rectification of a deficit. The generally positive results
obtained by these studies and the absence of any infor-
mation concerning the beneficial effects of delayed treat-
ment have been evaluated by the Guideline group as
strong indirect evidence for a prompt rectification of
existing deficits.
Chapter 3: Differences between
peri-interventional and ICU patients
Referenced literature:94,98,99
The key questions of Chapter 3 were withdrawn, as they
were not clinically relevant in their present form. The
relevant questions will be answered for their specific
patient groups in the chapters below.
Chapter 4a: Differences between colloids and
crystalloids in peri-interventional patients
Referenced literature:33,98,100–147Statement S-3 GoRBased on the available data, there is no indication that peri-inter-
ventional therapy with 6% HES 130, gelatin or albumin is associ-
ated with renal insufficiency—Background to statement S-3
No evidence was found for renal insufficiency associated
with peri-interventional administration of colloids, HES,gy. Unalbumin and gelatin as volume substitutes in contrast to
crystalloids as a volume substitute. The consensus
statement is based substantially on the most recent
review available for this key issue: this review includes
data on renal insufficiency from a total of 17 clinical
trials.126Recommendation 4a-1authorized reproduction of this article is pGoRColloid solutions (6% HES and gelatin) may be considered equal to
crystalloids as volume substitutes in the peri-interventional therapy
of acute hypovolaemia0Background to recommendation 4a-1:
The administration of 6%HES 130 and gelatin as colloids
in contrast to crystalloids as a volume substitute was
systematically reviewed in two meta-analyses. Gattas
et al.98 analysed 1608 patients from 25 studies, and Martin
et al.126 analysed 1230 patients from 17 studies. Both
systematic reviewswere able to show that there is currently
no demonstrable association between the administration
of HES 130/0.4 and gelatin and greater morbidity or
mortality. In particular, no changes in serum creatinine
and calculated creatinine clearance or in the incidence of
acute renal failure were found to be present in the peri-
interventional context.One limitation is that patientswere
followed up only for short periods in the present studies.Recommendation 4a-2 GoRBalanced crystalloid and/or balanced colloid solutions should be
used for peri-interventional volume substitutionBThe Management Board of the German Sepsis Society (DSG) commented on
this recommendation in the scope of the external appraisal as follows: the DSG is
unable to approve this recommendation.
Background to recommendation 4a-2
The recommendation to use balanced solutions was sub-
stantially influenced by a series of endpoints classified as
surrogate and supported in particular by the association –
considered to be well substantiated – of unbalanced
solutions and hyperchloraemia and acidosis, with adverse
effects on mortality and other endpoints such as infection
and renal insufficiency.143,148–150 These studies analysed
the differential effects of balanced versus unbalanced
solutions in general, for both crystalloid and colloid
solutions.
The grade of recommendation (GoR B) reflects the fact
that, in terms of the mortality endpoint, the studies and
patient numbers available for analysis are exceptionally
low. Accordingly, no adequately corroborated statements
can be made in this context, and the recommendation
for using balanced solutions is therefore based on the
summary analyses of the other endpoints beyond that of
mortality.rohibited.
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Intravascular volume therapy in adults 505Recommendation 4a-3right © European Society of AnaesthesioGoRTo optimise intraoperative haemodynamic values, synthetic colloid
solutions (6% HES 130/gelatin) may be used for pre-loading prior
to spinal anaesthesia0The Management Board of the German Sepsis Society (DSG) commented on
this recommendation in the scope of the external appraisal as follows: the DSG is
unable to approve this recommendation.
Background to recommendation 4a-3
For this key issue, there are a large number of randomised
controlled studies that use a variety of discrete study
designs to investigate a small number of patients.62–65
Accordingly, no statement on patient-relevant endpoints
can be derived from the studies. An additional limiting
factor to be considered when making any comparison is
that deciding on the most suitable ‘volume therapy’ –
particularly when taking the ‘patient population, inter-
vention, comparitor, outcome’ principle into account –
cannot be considered within a properly defined goal. In
light of the pronounced weakness of the available data,
there are no grounds for assuming that the equivalence of
the infusions is proven, despite the absence of a differ-
ence in mortality. Consequently the Guideline group
achieved consensus on a statement that clarifies this
circumstance and offers a ‘may’ recommendation (GoR
0) for the consideration of available synthetic colloids as
equivalents for preloading before spinal anaesthesia to
optimise intraoperative haemodynamic values.Recommendation 4a-4 GoRA lack of data on child safety means that antepartum administration
of colloids to pregnant and breastfeeding women must be limited to
cases of emergency onlyABackground to recommendation 4a-4
Pregnant and breastfeeding women present a special
situation in which potential benefits for the mother must
be balanced against risks for the fetus. These consider-
ations are properly taken into account by this recommen-
dation, which operates on the basis that no data on the
fetal transfer of synthetic or natural colloids are available,
and a potential risk for the fetus cannot be safely ruled
out. Studies are both feasible and necessary for this
situation.
Specific indications – such as preemptive volume therapy
during secondary caesarean section under epidural anaes-
thesia – were discussed at length by the Guideline group.
No consensus was reached on a recommendation, how-
ever, because of a lack of evidence.
Chapter 4b: Differences between colloids and
crystalloids in ICU patients
Referenced literature:4,98,111,151–170logy. UNB: ICU patients within the meaning of this guideline
are either critically ill with severe acute (or acute on
chronic) organ dysfunction or organ failure, or are free
from organ dysfunction but cannot be monitored outside
an ICU for other reasons.nStatement S-4authorized reproduction of this article is 
Eur J Anaesthesiol 2016; 33:488–GoRAs the available studies offer contradictory results and exhibit
methodological deficiencies, the Guideline group recommends
conducting randomised studies that contrast colloid administration
(6% HES 130/gelatin/albumin) with crystalloid in critically ill
patients. The group calls for the consideration of immediate study
enrolment and the application of the measures and targets agreed in
this Guideline for volume therapy indication and management—Background to statement S-4
The administration of HES to critically ill ICU patients
has been investigated by multiple randomised controlled
trials.156,164,166 A significant correlation is seen between
the administration of HES and the need to provide renal
replacement therapy.111 In the 6S study, the adminis-
tration of HES was associated with a negative outcome –
in terms of mortality and renal insufficiency – compared
to crystalloids.166 No difference in mortality was estab-
lished by the CHEST study, which investigated 7000
patients.164 As a result, the EMA convened a pharma-
covigilance risk assessment in 2013, which classified the
use of HES in critically ill patients as contra-indicated.
The limitation of those studies that report an adverse
outcome following treatment with HES is related solely
to the method used for the administration of HES (see
below) and not to theHES itself. There are also data from
a randomised controlled multicentre trial,151 which
demonstrated a benefit because of colloids, including
HES, in terms of 90-day mortality. As the primary trial
objective had been defined as a difference in 28-day
mortality, the study returned a negative outcome. A
key difference to earlier studies was that patients had
been enrolled immediately without a declaration of con-
sent being given by relatives or carers. Accordingly, this
study was the first study capable of documenting the
initial septic shock phase.
The trial protocol of the VISEP study156 permits no
insights into the decisive early phase of treatment of
patients with septic shock, because they could be
enrolled up to 24 h after diagnosis on the regular ward
and up to 12 h on the ICU. Within this period, the
patients were given a maximum of 1000ml of artificial
colloids, including HES solutions. In the 12 h before
study enrolment, 160/275 patients in the Ringer’s lactate
group and 155/262 patients in the HES group received
median volumes of 700ml (interquartile range: 500–
1000) and 979ml (interquartile range: 500–1000) of
colloids respectively, including HES and gelatin, and
in addition to crystalloid volume substitute. This resultedprohibited.
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stabilised before registration in the study (mean arterial
pressure>65mmHg, ScvO2> 70%, CVP> 8mmHg). In
the two ‘clinical/pragmatic’ trials, 6S166 and CHEST,164
no protocol was provided for the indication, monitoring
and management of volume therapy. Nor was there any
algorithm for assessing the fluid response of patients
(primarily clinical assessment, based on Surviving Sepsis
Campaign criteria). In both studies, the contraindications
relevant for patients with renal insufficiency, as listed in
the Surviving Sepsis Campaign, were disregarded and, in
addition, the maximum dose recommended for the HES
solution was considerably exceeded by the VISEP study.
Despite their methodological limitations, the results of
these studies are nonetheless important. They highlight
the fact that the cumulative dose of the colloid is clearly
of great importance for patients suffering from severe
sepsis and septic shock, and that the ‘pragmatic use’ of
HES cannot be considered to be safe following initial
stabilisation for septic patients not in shock.
A meta-analysis of 30 studies with 2700 patients revealed
that the use of gelatin compared to crystalloids/HES/
albumin is not associated with elevated risks of mortality
or renal insufficiency.170
Whether or not the use of colloids in intensive care
medicine is important for the safe and rapid haemody-
namic stabilisation of critically ill patients in shock within
the first 6 h cannot be established on the basis of the
available data. It should be noted that the targets for the
indication and management of volume therapy, for which
a consensus was achieved in this Guideline, have not
been considered by any study. The results of a random-
ised controlled pilot study suggest that, in patients with
sepsis-induced hypoperfusion, the microcirculatory
recruitment achieved by early goal-oriented treatment
is improved by the use of HES compared to the use of
0.9% sodium chloride (NaCl).158
In light of the above, the Guideline group achieved
consensus on a statement that clarifies this circumstance
and advocates the performance of randomised studies
that contrast colloid delivery (6% HES 130/gelatin/albu-
min) with crystalloid delivery in critically ill patients. The
group calls for the consideration of immediate study
enrolment and the application of the measures and tar-
gets agreed in this Guideline for the indication and
management of volume therapy.i
ERecommendations 4b-1, 4b-2, 4b-3ght © European Society of Anaesthesiolo
ur J Anaesthesiol 2016; 33:488–521GoRAs a rule, volume substitution in ICU patients should be undertaken
using crystalloid solutionsBHES must not be used in critically ill patients until the facts have
been settled by investigation as requested. Its use for haemorrhagic
shock must be very carefully consideredAIf, in the physician’s opinion, a case of acute hypovolaemia cannot
be adequately treated using crystalloids alone, these may be
supplemented by the use of gelatins and human albumin0gy. UnBackground to recommendations 4b-1, 4b-2,
4b-3
In several randomised controlled trials, crystalloids given
to critically ill ICU patients were associated with
improved survival (6S)111,166 and fewer instances of renal
insufficiency (VISEP/CHEST)156,164 compared to HES.
Despite the methodological limitations of these studies,
which are reflected in the GoR B, crystalloids were not
associated with greater side effects. Accordingly, consen-
sus was achieved by the Guideline group for this
general recommendation.
The administration of HES to critically ill ICU patients
has been investigated by multiple randomised con-
trolled trials (VISEP, 6S and CHEST).156,164,166 A
significant correlation is seen between the adminis-
tration of HES and the need to provide renal replace-
ment therapy.111 In the 6S166 study, the administration
of HES was associated with a negative outcome in
terms of mortality and renal insufficiency compared
to crystalloids.
Accordingly, the use of HES in critically ill ICU patients
is not recommended (high GoR).
In contrast to the above, one randomised controlled
multicentre trial (CRISTAL)151 demonstrated a benefit
from colloids, including HES, in terms of the 90-day
mortality. As the primary trial objective had been defined
as a difference in 28-day mortality, the study returned a
negative outcome.
A meta-analysis of 30 studies with 2700 patients also
revealed that the use of gelatins compared to crystalloids/
HES/albumin is not associated with increased risks of
mortality or renal insufficiency.170 In a randomised con-
trolled trial, the administration of gelatin compared to 6%
HES 200/0.62 was associated with lower renal insuffi-
ciency. In an Australian study investigating septic
patients, 4% albumin was not significantly (P¼ 0.09)
better than 0.9% NaCl.159
In intensive care medicine, the rapid haemodynamic
stabilisation of shocked patients within the first 6 h is
important to outcome. As the CRISTAL study demon-
strated a significant benefit in outcome with the use of
colloids after 90 days, the third recommendation supports
supplementary colloidal volume substitution with gelatin
or albumin for critically ill patients in intensive care
medicine.
A randomised controlled pilot study investigating criti-
cally ill patients with abdominal compartment syndrome
showed that colloidal solutions in volume therapy were
associated with a positive influence on a series of end-
points classified as surrogate, and that their use could
therefore be considered.157 However, the reported
benefits have not been adequately validated by study
data.authorized reproduction of this article is prohibited.
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Intravascular volume therapy in adults 507Recommendation 4b-4right © European Society of AnaesthesioGoRBalanced crystalloid and/or balanced colloid solutions should be
used for volume substitution in ICU patientsBBackground to recommendation 4b-4
The recommendation to use balanced solutions was sub-
stantially influenced by a series of endpoints classified as
surrogate that were supported by the well substantiated
association between unbalanced solutions and hyperchlor-
aemia and acidosis, with adverse effects on mortality,
infection and renal insufficiency.143,148,150,168,171
These studies analysed in the intervention arms inves-
tigated the differential effects of balanced versus unba-
lanced crystalloid and colloid solutions in general.
The grade of recommendation (GoR B) reflects the fact
that, in terms of the mortality endpoint, the studies and
patient numbers available for analysis are exceptionally
low. Accordingly, no adequately corroborated statements
can be made in this context, and the recommendation for
using balanced solutions is therefore based on the sum-
mary analyses of the other endpoints beyond that
of mortality.
Chapter 5a: Differences between colloids in
peri-interventional patients
Referenced literature:98–100,111,115,121,126,130,133,135,138,140,
141,143,160,172–209Statement S-5 GoRAs a result of low event rates involving the mortality endpoint and a
lack of data on fundamental morbidity endpoints, no recommen-
dations for the preferential use of a colloid group (human albumin,
gelatin or HES) can be derived from the literature—Recommendation 5a-1 GoR
In the event of an existing indication for the administration of a
colloidal volume substitute, human albumin, gelatin and HES may be
considered as equivalent for use in peri-interventional volume
substitution0In the scope of the external appraisal, the Management Board of the DSG
commented as follows on recommendation 5a-1, on the equivalence of human
albumin, gelatin and HES for peri-interventional use: the DSG is unable to
approve this recommendation.
Background to statement S-5 and
recommendation 5a-1
No significant differences were found between the
colloids investigated, HES, albumin and gelatin, in terms
of the mortality associated with these volume substi-
tution solutions. The conclusion reached is based sub-
stantially on the most comprehensive review available for
this key issue, which includes data on mortality from a
total of 57 clinical trials.179
In light of the pronounced weakness of the available data,
there are no grounds for assuming the proven equivalencelogy. Uof the solutions, despite the absence of a difference in
mortality. Consequently, the Guideline group achieved
consensus on a statement that clarifies this circumstance
without a grade of recommendation, offering a ‘may’
recommendation (GoR 0) for the consideration of avail-
able synthetic and natural colloids as equivalents, insofar
as their use is indicated.
In a primarily perioperative context, and for the treat-
ment of volume depletion, the data available to date offer
no indication of a benefit for one of the above-mentioned
colloidal solutions (group effect) in terms of efficacy or
the potential for side-effects.
Another aspect requiring consideration is that the con-
clusions drawn are for the effects from all preparations
within a group, making them potentially inadmissible for
individual preparations. It is not surprising that consider-
ably less data from randomised controlled trials are avail-
able to support comparisons of this kind. As differences in
mortality are also generally absent, no reliable con-
clusions can be drawn.nRecommendation 5a-2authorized reproduction of this article is 
Eur J Anaesthesiol 2016; 33:488–GoRIf colloidal volume substitution is used in peri-interventional care, the
solution must be selected according to legal, (transfusion) medical,
organisational, economic and logistical principlesABackground to recommendation 5a-2
No reliable conclusions can be drawn for the differential
use of colloidal volume substitution in a perioperative
context if the endpoint is mortality. Consensus has been
achieved for a strong recommendation that additional
endpoints such as allergenic potential should be used as a
basis for decision-making about the solution for colloidal
volume substitution, alongside logistical and financial
aspects (storage, mode of delivery and documentation
effort).
The recommendation, with a strong grade of recommen-
dation, supports both general (for specific operative areas
and care units) and case-by-case (individual patient man-
agement) decision-making for or against a specific group
or a specific preparation for colloidal volume substitution
in a perioperative context. Explicit reference is made to
the fact that other regulatory frameworks need to be
properly accounted for by such decision-making. These
include the provisions of the German Transfusion Act,
the ‘Guidelines for the Preparation of Blood and Blood
Components and the Use of Blood Components (Hae-
motherapy)’ and recommendations made by the German
Medical Association, such as ‘Cross-Sectional Guidelines
for Therapy with Blood Components and Plasma Deriva-
tives’.
Aside from the price, which has strong regional variations
and, in the authors’ opinion, should be assigned second-
ary importance at most when there are pertinentprohibited.
521
Copyr
508 Marx et al.advantages for use (documentation effort and storage),
the organisational and logistical aspects of handling
different solutions have a strong bearing on convenience
of use and ultimately choice in routine clinical practice.
One example of this is the batch documentation necess-
ary for specific preparations that can constitute a serious
logistical disadvantage for certain operational units. A
lack of compressibility in the container in which the
volume substitution solution is provided can be counter-
acted by timely delivery for volume substitution, and
thus the achievement of rapid haemodynamic stabilis-
ation.i
ERecommendation 5a-3ght © European Society of Anaesthesiolo
ur J Anaesthesiol 2016; 33:488–521GoRIf colloidal volume solutions are used in peri-interventional care,
consideration of metabolic and other endpoints (alkali deficit, pH
value, chloride concentration) means balanced solutions should be
usedBBackground to recommendation 5a-3
The conclusion reached is based substantially on the
most comprehensive review available for this key issue.
This review includes 14 publications from a total of 13
clinical trials.180
The analysis considered the differential effects of
balanced versus unbalanced solutions in general, and
therefore included both crystalloid and colloidal solutions
in the intervention arms investigated. Notwithstanding
this fact, the effects are nonetheless seen in the endpoints
investigated, with the exclusion of the intervention stu-
dies in which a specific crystalloid or colloidal volume
substitute was used.
The grade of recommendation (GoR B) reflects that, in
terms of the mortality endpoint, the studies and patient
numbers available for analysis are exceptionally low.
Accordingly, no adequately corroborated statements can
bemade in this context, and the recommendation for using
balanced solutions is therefore based on the summary
analyses of other endpoints beyond that of mortality.
The recommendation to use balanced solutions was
influenced substantially by a series of endpoints classified
as surrogate and also supported in particular by the well
substantiated association between unbalanced solutions
and hyperchloraemia and acidosis, with adverse effects
on mortality and other endpoints such as infection and
renal insufficiency.148–150,171Recommendation 5a-4 GoRIn selecting a colloidal volume substitution solution, individual
aspects such as allergic potential, previous renal impairment, inter-
ference with blood coagulation and co-morbidities, must be con-
sidered, alongside intervention-specific and medical (transfusion)
aspectsAgy. UnBackground to recommendation 5a-4
Alongside legal, medical (transfusion), organisational,
logistic and economic considerations, this recommen-
dation also properly accounts for the differences between
the various colloids of natural or synthetic origin in their
potential to cause adverse side-effects. Although such
considerations need not mean that one or other of these
colloids is generally preferable in a peri-interventional
context, their use in specific cases must nevertheless be
properly accounted for. One example is HES, which is
contraindicated in patients with limited renal function or
where renal replacement therapy is required. In
addition, the presence of an allergic disposition may
be seen as a relative contraindication to the use of
preparations containing gelatin.210 Secondary consider-
ations such as the presence of hypoalbuminaemia in the
context of a volume deficit can tip the scales in favour of
the use of a specific volume substitute (such as albumin),
even if the hypoalbuminaemia does not itself actually
require compensation.
For a specific case, such information and recommen-
dations can, because of a multitude of conceivable cir-
cumstances and a lack of evidence from clinical research
for the specific situation, be considered as secondary
decision-making criteria at best. For this reason the
Guideline group necessarily and explicitly takes into
account the fact that adequate study data will never
be available to substantiate all of the circumstances
possible, and hence that there are good reasons for an
approach or methodology orientated toward the patho-
physiology concerned.
Chapter 5b: Differences between various
colloids in ICU patients
Referenced literature:4,6,7,86,98,99,111,152–154,163,170,171,179,
209,211–213Recommendation 5b-1authorized reproduction of this article is pGoRHypo-osmolar solutions must not be used for volume therapy in ICU
patients with severe traumatic brain injuryABackground to recommendation 5b-1
For patients with a severe traumatic brain injury, volume
therapy with 4% albumin was associated with signifi-
cantly higher 24-month mortality (RR 1.88; 95% CI
1.31–2.70). The figures are derived from posthoc analysis
of 460 patients from a subgroup analysis of the SAFE
study.214 The point in question is the influence of hypo-
osmolar albumin on the development of a vasogenic and/
or cytotoxic cerebral oedema, and whether the effect is
substance-specific or osmolar in nature cannot be deter-
mined from the data currently available. Nevertheless,
there is a general consensus that the use of 4% albumin
cannot be recommended at present for traumatic brain
injury patients. Additional clinical studies are needed to
enable further progress.rohibited.
Cop
Intravascular volume therapy in adults 509Chapter 6a: Differences between crystalloids
in peri-interventional patients
Referenced literature:95,105,121,127,130,140,146,176,180,193,201,
215–243yStatement S-6right © European Society of AnaesthesioGoRAs a result of low event rates involving mortality and a lack of data
from controlled trials on fundamental morbidity, no recommen-
dations for the preferential use of a crystalloid group can be derived
from the literature—Recommendation 6a-1 GoR
Isotonic NaCl must not be used as a peri-interventional volume
substituteABackground to statement S-6 and
recommendation 6a-1
Significant differences between various crystalloid
solutions in relation to their associated mortality follow-
ing peri-interventional administration can neither be
proven nor safely excluded. The conclusion reached is
based substantially on the most comprehensive review
available for this key issue. It includes 14 publications
from a total of 13 clinical trials.180
The analysis considered the differential effects of
balanced versus unbalanced solutions in general, and
therefore also included colloidal solutions in the inter-
vention arms investigated. Nonetheless, the effects such
as comparable outcome in terms of mortality are demon-
strated in the endpoints investigated but with the exclu-
sion of the intervention studies where a colloidal volume
substitute was used. The conclusions drawn concerning
the endpoints of mortality and morbidity properly take
into account the fact that the numbers of studies or
patients that are still available after applying this premise
(exclusion of studies with colloidal solutions in the inter-
vention arms) are vanishingly small. Accordingly, no
sufficiently well founded statements can be made.
Despite this, the members of the consensus conference
unanimously agreed (100% agreement with the recom-
mendation) that a nonphysiological solution, namely
isotonic saline, must not be used for planned peri-inter-
ventional volume substitution.Recommendation 6a-2 GoRBalanced crystalloid isotonic electrolyte solutions must be used for
peri-interventional volume substitutionABackground to recommendation 6a-2
As noted above with regard to colloidal volume substi-
tution, the recommendation to use balanced solutions
was influenced substantially by a series of endpoints
classified as surrogate and supported in particular by
the well substantiated association between unbalancedlogy. Usolutions and hyperchloraemia, which is increasingly
observed following the use of an isotonic saline, with
adverse effects on mortality and other endpoints such
as infection, renal insufficiency and acid-base bal-
ance.143,148,150,171
The available evidence supporting the use of balanced
crystalloid solutions as a factor influencing acid-base bal-
ance is more comprehensive than for the endpoint of
mortality. The data show that an unbalanced crystalloid
solution (0.9% NaCl) produced a lower pH value, plus a
larger alkali deficit and higher sodium and chloride values.
Despite this, it is too early to speak of an actual clinical
superiority. Nevertheless the known negative effects of
hyperchloraemic acidosis and its association with
unfavourable outcome necessitate a recommendation
in favour of the use of balanced solutions for volume
substitution in a perioperative context. This also implies
that, in the event of balanced solutions being unavailable,
isotonic saline may exceptionally be given for volume
substitution. The members of the consensus conference
voiced a strong recommendation (80% agreement for
GoR A) for the use and stockpiling of balanced solutions
in operational units that are regularly involved in the
provision of infusion therapy.
The recommendation to use ‘balanced solutions’ refer-
ences the group effects found in the meta-analysis per-
formed by Burdett et al. for all preparations within an
entire group (’balanced crystalloid solution’ versus ‘unba-
lanced crystalloid solution’). Potentially, these recom-
mendations may not fully reflect the actual effects of
individual preparations.81 It is not surprising that little
or no data at all (e.g. for use in distinguishing between
mortality) are available to permit a reliable statement to be
made on the superiority of individual solutions. However,
it may be currently assumed that, in the absence of
significant differences in clinical outcome (mortality)
between balanced crystalloid solutions compared to unba-
lanced crystalloid solutions (first and foremost 0.9%NaCl),
it is improbable that differences between specific balanced
crystalloid solutions will be significant and hence can be
considered negligible in the context of the data.
The recommendation does not take into account poten-
tial indications for the use of hypertonic NaCl solutions.
Solutions of this kind are also used in a perioperative
context, but in a limited manner (614 patients in 15
studies).82 Numbers are too small to permit comment
on the incidence of mortality and harm, but hypertonic
NaCl may have a place in the presence of an elevated
serum sodium level, although overall perioperative
demand is low. As a consequence the extent of the role
of general or individual use of hypertonic solutions in
peri-interventional volume therapy outside specialised
indications (small volume resuscitation) must remain
unresolved.nauthorized reproduction of this article is prohibited.
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ERecommendation 6a-3ght © European Society of Anaesthesiolo
ur J Anaesthesiol 2016; 33:488–521GoRAs they do not influence diagnostic criteria, balanced infusions
containing acetate or malate instead of lactate may be integrated
into the treatment algorithm for volume substitution in peri-interven-
tional patients0Background to recommendation 6a-3
Because studies are few and the solutions used hetero-
geneous, no information is available to support the associ-
ation of specific balanced infusion solutions with
improved postoperative (surrogate) outcome.
Currently this applies in particular to balanced infusions
containing anions able to enter the metabolic pool
(acetate and malate). Despite the advantage of not
inducing hyperchloraemia and in the absence of inter-
ference with lactate values when used as a diagnostic
marker (surrogate endpoint), an effect on outcome is
not guaranteed. Because these solutions are adminis-
tered in a balanced form, a similar effect to balanced
crystalloid infusions must be assumed. Conscious of the
lack of clinical data on superiority, the consensus
process resulted in a weak recommendation to ‘con-
sider’ these solutions (GoR 0), with strong level of
agreement.
Chapter 6b: Differences between crystalloids
in ICU Patients
Referenced literature:162,168,171,244–248Recommendation 6b-1 GoRAn isotonic saline solution must not be used as a volume substitute
in intensive care medicineABackground to recommendation 6b-1
In comparison to isotonic saline, the use of balanced
solutions is associated with a significantly lower incidence
of hyperchloraemic acidosis within the first 48 h following
the start of treatment (hazard ratio 0.28; 95% CI 0.11,
0.70; P¼ 0.006).168 It has been postulated that hyper-
chloraemic acidosis influences haemostasis and also
gastrointestinal and cognitive function. A prospective
open-label pilot study investigating 760 patients who
were treated either with chloride-rich or chloride-poor
solutions (balanced solutions or chloride-poor 20% albu-
min) was able to show that treatment with chloride-rich
solutionswas associatedwith a significantly higher serum
creatinine level (P¼ 0.03), an increase in the incidence
of renal insufficiency (P< 0.001) and a greater need for
renal replacement therapy (P¼ 0.004).171 Based on the
available data, isotonic saline solutionsmust no longer be
used for volume therapy in intensive care medicine.
Instead, balanced isotonic electrolyte solutions must
be used as a volume substitute for critically ill ICU
patients.gy. UnRecommendation 6b-2authorized reproduction of this article is pGoRBalanced isotonic electrolyte solutions must be used as a volume
substitute for critically ill ICU patientsABackground to recommendation 6b-2
As the use of balanced isotonic electrolyte solutions is
recommended both for hospitalised adults receiving peri-
interventional treatment and for critically ill ICU
patients, we refer to the background information pro-
vided for the consensus recommendation 6a-2.Recommendation 6b-3 GoRBalanced electrolyte solutions containing acetate or malate instead
of lactate may be used as a volume substitute for critically ill ICU
patients0Background to recommendation 6b-3
Please refer to the background information for the 3rd
consensus recommendation 6a-3.
Chapter 7a: Management of volume therapy
in peri-interventional patients
Referenced literature:8,11,13–24,30,32–35,38,40,50,53,56,58,59,61,
63–65,68–71,73–76,87,101,123,249–263Recommendations 7a-1, 7a-2 GoRFor the management of volume therapy in patients at a high level of
riskM at the perioperative stage, monitoring methods that facilitate
optimisation of the volume status by means of flow-based (stroke
volume) and/or dynamic preload variables (SVV, PPVar) may be
used0M Patients with a preexisting impaired cardiovascular reserve
(elderly patients with hip fractures) or interventions entailing large
volume shifts (prolonged surgery in the abdomen)
Flow-based variables used to manage volume therapy should be
integrated into a treatment algorithmBBackground to recommendations 7a-1 and 7a-2
Although study quality is dubious, the available data on
the use of flow-based (stroke volume and cardiac output)
or dynamic preload variables (SVV and PPVar) for peri-
operative improvement of volume status through increas-
ing DO2 to the periphery, suggest that a favourable effect
on (combined endpoints for) morbidity is possible. It is
difficult to issue a statement on the value of volume status
optimisation in isolation because the impact of preload
changes (in accordance with the Frank–Starling mech-
anism) is confounded by the administration of inotropic
agents. Mortality in the context of the (elective) pro-
cedures investigated is low overall and statements
addressing the impact on mortality are not possible.
Peri-interventional optimisation of the volume status
with the aim of raising oxygen availability is unlikely
to have an adverse influence on clinical endpoints.rohibited.
Cop
Intravascular volume therapy in adults 511On the basis of available data, no statement can be made
on the application of surrogate markers of haemody-
namics to fluid therapy.
A recently conducted review of the perioperative optim-
isation of blood flow and oxygen transport included 31
studies with a total of 5292 participants.264 The period of
study started 24 h before and ended 6h after surgery.
Haemodynamic targets included cardiac output, the car-
diac index, DO2 and DO2I, VO2 and VO2I, the stroke
volume and stroke volume index, ScvO2, oxygen extrac-
tion rate and lactate. The review did not consider the
importance and validity of the chosen haemodynamic
targets. Treatment with vasoactive inotropic agents or
volume did not achieve any reduction in mortality. The
length of hospital stay was reduced by 1 day, however.
The optimisation of fluid delivery according to SVV was
investigated in a randomised study looking at elective
abdominal surgery.250 When SVV exceeded 10%,
3mlkgBW1 of a colloidal volume substitute was admi-
nistered. Dobutamine was given where the cardiac index
was less than 2.5 lmin1m2, so as to place it in a target
range between 2.5 and 4 lmin1m2. Patients in the SVV
group (n¼ 60) received a greater intra-operative volume
than the control group (n¼ 60). In the SVV group fewer
hypotensive events were registered; the lactate level was
also lower toward the end of the operation. Complications
occurred significantlymore often in the control group (58.3
vs. 30%, P¼ 0.0033).
In female patients with severe eclampsia, PLR with
simultaneous determination of the velocity time integral
of subaortic blood flow via Doppler echocardiography
permitted a reliable estimate to be made of volume
responsiveness.253
Intra-operative use of oesophageal Doppler measure-
ment of aortic blood flow was investigated by systematic
review249 which included five studies with 420 patients
receiving a major abdominal surgical intervention. FTc in
the descending aorta was used to optimise volume with a
target value of more than 350ms. The intervention group
had a shorter hospital stay, fewer complications and fewer
ICU admissions.
Patients monitored with oesophageal Doppler receiving
major abdominal surgery, with volume therapy managed
bymeans of FTc in the descending aorta, had shorter hos-
pital stays and a more rapid restoration of bowel func-
tion.257
Total 90 patients were monitored during surgery with
oesophageal Doppler;34 respiratory SVV proved to be an
excellent tool for predicting volume responsiveness
(AUC value for the ROC curve 0.91) but FTc did not
permit any reliable estimates to be made (AUC value for
the ROC curve 0.49).yright © European Society of Anaesthesiology. UIn all 40 patients (with preserved left ventricular pump
function) were investigated during a bypass operation
(off-pump).35 SVV and PPVar were good predictors of
volume responsiveness (AUC value for the ROC curve
0.823 and 0.808) but CVP, PAOP, the left ventricular
end-diastolic area index (determined using echocardio-
graphy) and GEDVI did not permit any reliable estimates
to be made.
Use of PPVar in surgical high-risk patients to esti-
mate volume responsiveness (goal of volume thera-
py¼PPVar <10%) reduced the length of hospital
stay and the number of complications in the interven-
tion group.123
A systematic Cochrane Review analysed the signifi-
cance of volume therapy optimisation in patients
receiving surgery following a proximal femoral frac-
ture265 but only three studies with a total of 200
patients were admissible. Studies that failed to monitor
haemodynamic status of the intervention group with
transoesophageal Doppler or pulse contour analysis
were excluded. No relevant benefits for protocol-based
haemodynamic optimisation of fluid therapy were
found, but the numbers studied may have been too
small for a definitive conclusion.
A systematic review investigated the significance of
perioperative goal-oriented haemodynamic optimisation
through volume loading during surgical procedures. A
total of 24 studies were included in the review. The
patient groups, the monitoring procedure used and even
the target variables for the respective protocols reveal a
high degree of variation overall.262Despite this therewas
a reduction in postoperative renal damage [Odds ratio
(OR) 0.59].
We may draw the following conclusions: Tnhe patient groups investigated are highly hetero-
geneous. The protocols deployed and the target variables used
to estimate volume responsiveness are also highly
heterogeneous. Pressure-based static variables such as CVP and/or
PAOP are not suitable for estimation of volume
responsiveness. SVV and PPVar are suitable for the estimation of
volume responsiveness. Oesophageal Doppler offers an option for the
continuous monitoring of the volume status. Currently there are no binding protocols available for
volume therapy management. However, perioperative
volume therapy should be guided by treatment
algorithms that primarily use flow-based target vari-
ables for haemodynamic optimisation.authorized reproduction of this article is prohibited.
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512 Marx et al.Chapter 7b: Management of volume therapy
in ICU patients
Referenced literature:9,10,25–29,31,36,37,39,41–49,51,52,54,55,57,
62,66,67,72,75,76,266,267i
ERecommendation 7b-1ght © European Society of Anaesthesiolo
ur J Anaesthesiol 2016; 33:488–521GoRVolume status must be physically assessed (skin turgidity, assess-
ment of the mucous membranes, axilla and eyeball) in addition to
instrument-based clinical examination, as part of volume therapyABackground to recommendation 7b-1
Clinical examination attempts To determine whether the symptoms are being caused
by hypovolaemia; And if so, to determine the degree of hypovolaemia.77
Examination of skin turgidity assesses the elastic recoil
of the skin, which is pulled up between finger and
thumb. The protein elastin is primarily responsible for
this recoil and is generally determined by the moisture
content of the skin.268 A moisture loss of only 3.4% (by
weight) prolongs the recoil of the skin after being
pinched by a factor of 40. Elastin degradation also
occurs with advanced age. Skin turgidity therefore
decreases with age. Normal skin turgidity has never
been scientifically assessed; nor are there any studies
that describe the exact technique that should be used to
determine it.77
Cellular dehydration, interstitial fluid depletion and poor
perfusion are responsible for a multitude of other clini-
cally accepted signs of hypovolaemia. These signs
include a dry tongue, a dry axilla and soft eyeballs. Only
a handful of studies are available that describe the
precision of these clinical signs as evidence of hypovo-
laemia. The finding of a dry axilla increases the likelihood
of hypovolaemia (positive OR 2.8; 95% CI 1.4 to 5.4),
even though sensitivity is only 50%,269 and the finding of
a moist axilla weakens this likelihood but only minimally
(negative OR 0.6; 95% CI 0.4 to 1.0).
In a study investigating 55 older patients with suspected
hypovolaemia, seven clinical signs (confusion, weakness,
slurred speech, dry mucous membranes, dry tongue,
furrowed tongue and sunken eyeballs) correlated best
with serum sodium and the serum urea to creatinine
ratio.270 The absence of dry mucous membranes, sunken
eyeballs and a furrowed tongue are the best indicators for
the absence of hypovolaemia.
Despite a lack of high-quality evidence, a thorough
physical examination should always be performed, and
the findings obtained should be critically cross-checked
with the results of instrument-based examination and
invasive haemodynamic monitoring.gy. UnRecommendations 7b-2, 7b-3, 7b-4authorized reproduction of this article is pGoRFor volume therapy management in adults, and especially in the
case of ventilated ICU patients, monitoring that permits an esti-
mation of volume responsiveness should be used: flow-based
(stroke volume) and/or dynamic preload variables (SVV and PPVar)
are superior to static variables (CVP and PAOP)AFor volume therapy, volume responsiveness should be determined
repeatedly by measuring the stroke volume or a dynamic preload
variable, including transaortic stroke volume variationBIf possible, a positional manoeuvre facilitating autotransfusion (Tren-
delenburg position, passive leg raising) should be performed as part
of management of volume therapyBBackground to recommendations 7b-2, 7b-3,
7b-4
Despite the lack of scientifically acceptable evidence,
CVP continues to be deployed in the management of
volume therapy. As recently as 2008, a meta-analysis
demonstrated the inadequate agreement of CVP with
volume status. Changes in CVP did not correlate with
changes in stroke volume following defined volume
loading (volume challenge).271 The AUC value for the
ROC curve was 0.56. Recently, the significance of CVP in
a broad range of clinical scenarios was once again inves-
tigated by a meta-analysis of 43 studies.79 Of these, 22
studies concerned intensive care patients, 20 studies
analysed the use of CVP within operative monitoring
and one study was conducted with study participants.
To satisfy the inclusion criteria, a study must have
investigated CVP as a predictor of volume responsive-
ness, which was defined as an increase in cardiac output
and stroke volume following a volume challenge or after
PLR. Most studies defined volume responsiveness as an
increase in cardiac index or the stroke volume index by at
least 15%. The volume challenge consisted of 500ml of
intravenous fluid (typically HES). Data for the ROCwere
available in 20 studies. Overall, 57% 13% of patients
were volume-responsive. The average CVP when
measured initially was 8.2 2.3mmHg in the volume-
responsive group and 9.5 2.2mmHg in non-volume
responders. The AUC value for the ROC curve was
0.56 (95% CI 0.54; 0.58). No difference was seen between
intensive care and operating theatre patients. The same
results were also obtained for cardiac surgery and non-
cardiac surgery patients. In all groups, there was no
correlation of the initial CVP measurement with the
change in cardiac index/stroke volume. Neither CVP
nor PAOP correlate with actual cardiac preload, nor was
there any linear relationship. CVP is typically measured
as the difference between the intravascular space and
atmospheric pressure. For ventricular filling, however,
transmural pressure – the difference between intra-
ventricular and pericardial pressure – is the
more relevant index. Intrapericardial pressure is not
available under clinical conditions, however. Accord-
ingly, the true transmural pressure remains unknown
and the pressure value measured against atmosphericrohibited.
Cop
Intravascular volume therapy in adults 513pressure is routinely used as a surrogate for the filling
pressure. In the special case of ventilated patients
receiving either intermittent positive pressure venti-
lation or positive endexpiratory pressure, CVP will
actually increase without any concomitant increase in
end-diastolic ventricular volume.272
CVP also depends on the intravascular volume and per-
ipheral vascular tone, right ventricular compliance and
pulmonary vascular resistance. Misleadingly high values
can occur during treatment with vasopressors. The use of
vasopressor agents can result in a substantial increase in
CVP without any change occurring in the intravascular
volume. Clinically relevant tricuspid insufficiency can
also interfere with measured values to a significant
degree.272
A retrospective study investigated 96 ventilated
patients with severe sepsis and septic shock.273 All
patients were monitored by means of a pulmonary
arterial catheter. CVP and PAOP were measured at
the end of expiration. In addition, care was taken
to ensure that the catheters were placed in West’s zone
3. The indication for a volume challenge was defined
as a clinical sign of acute circulatory collapse or signs
of hypoperfusion. This required all patients to
receive an infusion of 500ml 6% HES over 20min.
An increase in the cardiac index of at least 15% was
graded as a positive volume response (’responder’).
Pre-infusion CVP was not significantly different in
responders compared to nonresponders (8 4mmHg
vs. 9 4mmHg), whereas pre-infusion PAOP was sig-
nificantly lower in the responders (10 4mmHg vs.
11 4mmHg, P <0.05). A CVP of less than 8mmHg
had a positive predictive value of only 51%, whereas for
a PAOP less than 11mmHg it was only 54%. The
combination of CVP and PAOP did not improve the
prediction. Even in patients with a low stroke volume
index of less than 30mlm2, the predictive power of
CVP and PAOP for a positive volume response
remained inadequate.
In healthy study participants, changes in CVP and
PAOP before and after the administration of 3 l of
0.9% NaCl over 3 h did not correlate with changes in
the left ventricular enddiastolic volume (index).98 Nor-
mal static pressure measurements of CVP and PAOP
were entirely unable to reflect adequate filling of either
the right or the left ventricle. A CVP of 9mmHg
corresponded to a right ventricular end-diastolic volume
index between 50 and 90mlm2. Similar variability was
exhibited by PAOP. Here, an left ventricular end-dias-
tolic volume (index) between 50 and 80mlm2 was
found for a PAOP of 11mmHg.274 These data in healthy
study participants and also in seriously ill patients
and those with cardiovascular disorders in particular,
demonstrate an unhelpful relationship between static
preload variables and end-diastolic volume.yright © European Society of Anaesthesiology. UIn 22 ventilated patients with adult respiratory distress
syndrome receiving lung-protective ventilation therapy
(low tidal volume and high positive end-expiratory pres-
sure), various haemodynamic monitoring variables were
investigated for their ability to predict volume respon-
siveness.28 Here, PPVar provided the best AUC value at
0.768 for the ROC curve (CVP¼ 0.429, PAOP¼ 0.187,
GEDVI¼ 0.323, ITBVI¼ 0.323, SVV¼ 0.606).
In 42 patients with septic shock, the SVV was compared
with PPVar.37 Both methods were comparatively well
suited to predicting volume responsiveness. The AUC
value for the ROC curve was 0.92 for SVV and 0.916 for
PPVar. The optimum cut-off for SVV for predicting
volume responsiveness was 10%; the value was 12%
for PPVar.
In spontaneously breathing ICU patients, Doppler echo-
cardiography measurements of cardiac output and stroke
volume following PLR can be reliable indicators of
hypovolaemia.42 An increase of cardiac output or stroke
volume by more than 12% following PLR gave a good
AUC value for the ROC curve of 0.89 and 0.90 in
predicting volume responsiveness.
A systematic review investigated the significance of TTE
for estimating volume responsiveness in critically ill
patients.43 Included in this analysis were studies con-
sidering PLR and the determination of transaortic SVV,
the impact of respiration on transaortic SVV, and the
impact of respiration on IVC diameter. In all the studies
included, the AUC value for the ROC curve was over
0.90: accordingly, we may assume that echocardiography
measurement techniques offer an excellent means of
predicting volume responsiveness.
In 40 ventilated patients with septic circulatory collapse,
PPVar and SPV were well suited for use as predictors of
volume responsiveness (AUC value for the ROC curve
0.98 and 0.91).44 CVP and PAOPwere entirely unsuitable
for use as predictors of volume responsiveness (AUC
value for the ROC curve 0.51 and 0.40).nRecommendation 7b-5authorized reproduction of this article is 
Eur J Anaesthesiol 2016; 33:488–GoRUltrasound techniques (Doppler sonography, B-mode and TTE)
may be used for the management of volume therapy0Background to recommendation 7b-5
43A systematic review investigated the ability of TTE to
estimate volume responsiveness. This review excluded
TEE studies. Out of 3183 possible studies, only eight
studies were ultimately included in the systematic
review. Of these, five studies investigated Doppler echo-
cardiography measurement of transaortic SVV for esti-
mating volume responsiveness following PLR. All
studies demonstrated good sensitivity (77 to 100%) and
specificity (88 to 99%) in predicting an increase in strokeprohibited.
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514 Marx et al.volume or cardiac output by 10 to 15%. One study275
investigated volume responsiveness by measuring trans-
aortic stroke volume variation as a value dependent on the
inspiration and expiration of ventilated patients.Here, too,
the sensitivity and specificity of a stroke volume variation
of 9% were excellent (100 and 88%) for its use as a cut-off
for predicting volume responsiveness.
Two further studies investigated the respiratory-based
variation of the IVC diameter in ventilated patients.
Maxima and minima for the respiratory-dependent
diameter of the IVC were measured directly underneath
its confluence with the hepatic vein. IVC distensibility
was measured as a percentage index. The study from
Barbier et al.8 chose a distensibility index of 18%, whereas
12% was chosen by Feissel et al.28 In the first study,
sensitivity and specificity were 90%. In the second study,
a variation in the diameter of the IVC of over 12%
permitted the differentiation of volume-responsive
patients with a positive predictive value of 93% and a
negative predictive value of 92%.28
One limitation of the studies was the low number of
enrolled patients. Also there was variation between the
studies in terms of the quantity, nature and rapidity of
infusion of the intravenous fluids.
In critically ill patients, methodological limitations also
arise from unfavourable ultrasound conditions and inade-
quate expertise or experience on the part of the investi-
gators.i
ERecommendation 7b-6ght © European Society of Anaesthesiolo
ur J Anaesthesiol 2016; 33:488–521GoRIn the context of volume therapy management, ultrasound techniques
should be applied repeatedly to either prove or rule out the existence
of extravasations (e.g. pleura, abdomen, bowel or interstitium)BBackground to recommendation 7b-6
No prospective studies are available that investigate the
significance of detecting extravasations (e.g. pleura,
abdomen, bowel or interstitium) in the course of evalu-
ating a volume deficit or volume overload.Recommendation 7b-7 GoRFunctional haemodynamic monitoring measures (ventilation
manoeuvres, physical positional manoeuvres (PLR) or defined
volume loading (volume challenge)) may be used to enhance the
sensitivity of volume deficit recognition and for the management of
volume therapy0Background to recommendation 7b-7
As a rule, the functional haemodynamic measures in the
studies were supplemented by a volume challenge of
500ml HES 6% over 30min. Patients were defined as
volume-responsive if stroke volume or the cardiac output
(index) increased by 10 to 15%.gy. UnChanges in mean arterial pressure do not show good
agreement with changes in the cardiac index after a
defined volume challenge and are therefore unsuited
for use as estimators of volume responsiveness.54
By using PLR with simultaneous measurement of
the stroke volume with Doppler echocardiography,
volume responsiveness in spontaneously breathing
patients can be reliably predicted by an increase
in stroke volume of over 12% during the physical
body positional manoeuvre. The AUC value for the
ROC is 0.90 0.06 for the determination of stroke
volume.42
Stroke volume, radial pulse pressure and the maximum
velocity of blood flow in the femoral artery were
measured in spontaneously breathing patients (n¼ 34)
during a physical positional manoeuvre involving PLR.25
Volume responsiveness was predicted by a SVV of at least
10%with a sensitivity of 86% and a specificity of 90%, and
by a PPVar of at least 9% with a sensitivity of 79% and a
specificity of 85%, and by maximum blood flow in the
femoral artery with a sensitivity of 86% and a specificity
of 80%.
PPVar (threshold 13%) is a useful predictor of volume
responsiveness in septic ventilated patients (n¼ 40) with
circulatory collapse.44 Patients with a cardiac index of at
least 15% compared to the initial value following a
volume challenge were classified as responders. Measure-
ment of haemodynamic variables took place immediately
before and 30min. after volume expansion with 500ml
HES 6%. Pulse pressure variation revealed excellent
differentiation with an AUC value for the ROC curve
of 0.98 0.03. Sensitivity was 94% and specificity was
96% in predicting volume responsiveness. In this study,
patients were ventilated with a tidal volume of
8ml kgBW1.
During ventilation with a lower tidal volume (6 to
7ml kg1 ideal body weight) respiratory pulse pressure
variation is limited in its ability to differentiate when
used as a predictor for volume responsiveness.51 A
PPVar of at least 10% still shows reliable differen-
tiation, with an AUC value for the ROC curve of
0.74 (95% CI: 0.56 to 0.90). In a further study inves-
tigating ventilated septic patients given lung-protective
ventilation, pulse pressure variation was shown to be a
reliable predictor of volume responsiveness. A cut-off
of 6.5% had a sensitivity of 0.89 and a specificity of
0.90.31
In spontaneously breathing patients, PPVar and SVV
have limited sensitivity, and are thus less able to differ-
entiate when used as predictors of volume responsive-
ness.62 If the initial value is very high, however, and
without simultaneous right ventricular dysfunction,
volume responsiveness can also be predicted for spon-
taneously breathing patients.authorized reproduction of this article is prohibited.
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Intravascular volume therapy in adults 515Recommendation 7b-8right © European Society of AnaesthesioGoRFunctional haemodynamic variables must not be considered in
isolation when estimating the volume requirement and/or volume
responsiveness, but must be supplemented by the medical case
history and clinical examination resultsABackground to recommendation 7b-8
This is an assessment made by the experts, and the assess-
ment is not supported by evidence from relevant studies
(inclusion criteria for the studies are given in Table 2).
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